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Abstract: Cyclic dipeptides, also know as diketopiperazines (DKP), the simplest cyclic forms of pep-
tides widespread in nature, are unsurpassed in their structural and bio-functional diversity. DKPs, 
especially those containing proline, due to their unique features such as, inter alia, extra-rigid con-
formation, high resistance to enzyme degradation, increased cell permeability, and expandable abil-
ity to bind a diverse of targets with better affinity, have emerged in the last years as biologically 
pre-validated platforms for the drug discovery. Recent advances have revealed their enormous po-
tential in the development of next-generation theranostics, smart delivery systems, and biomateri-
als. Here, we present an updated review on the biological and structural profile of these appealing 
biomolecules, with a particular emphasis on those with anticancer properties, since cancers are the 
main cause of death all over the world. Additionally, we provide a consideration on supramolecular 
structuring and synthons, based on the proline-based DKP privileged scaffold, for inspiration in the 
design of compound libraries in search of ideal ligands, innovative self-assembled nanomaterials, 
and bio-functional architectures. 
Keywords: cyclic dipeptides; diketopiperazines; proline-based DKPs; drug discovery; privileged 
scaffold; supramolecular structuring 
 
1. Introduction 
Cyclic dipeptides, also known as cyclo-dipeptides, diketopiperazines (DKPs), piper-
azinediones, dioxopiperazines, or dipeptide anhydrides, are the simplest, naturally oc-
curring cyclic forms of peptides, commonly biosynthesized by a large variety of living 
organisms [1–4] and conserved in bacteria to humans [5,6]. They were first discovered in 
1880 and later studied by E. Fischer [7]. Once believed to be only protein artifacts or deg-
radation products, and therefore neglected, DKPs are now considered essential metabolic 
intermediates, and an interesting platform for therapeutic exploration [8]. DKPs possess 
all advantages of cyclic peptides. DKPs are an unsurpassed class of bio-molecules in their 
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structural and bio-functional diversity. Moreover, the ‘biosynthetic hooks‘ are a useful strat-
egy for the identification of the genes modifying the DKP ring to expand the chemical 
space of cyclic dipeptides [9,10]. Moreover, modified DKPs have recently emerged as an 
important pharmacophore in a number of theranostic settings. Notably, proline motif in-
troduces additional conformational and bio-functional value into the DKP-derived struc-
tures. The attractive features, such as extra rigidity, structural stability, and consequently, 
greater resistance to degradation by enzymes, higher bioactivity, specificity, selectivity, 
and efficacy, increased cell permeability, or binding affinity to specific targets, inherent 
biocompatibility, structural importance to biological systems [11,12] make proline-based 
cyclic dipeptides a promising alternative to currently used small molecule and macromol-
ecule pharmaceuticals.  
The mechanism of proline-based DKPs formation is described elsewhere [13]. 
DKPs are ‘diamonds in the rough‘, offering endless possibilities in future innovative 
therapies [14]. Therefore, since the earliest report on DKP in 1924 [15], an increasing de-
gree of attention to DKPs has been observed, and numerous scientific findings revealing 
their broad-spectrum biological activities have been reported in recent years. In particular, 
proline-based DKPs have diverse properties depending on structure and application, such 
as anticancer, antioxidant, neuroprotective, antiviral, antibacterial, anti-inflammatory, an-
tihyperglycemic, antiarrhythmic, immunomodulatory, antiparasitic, anthelmintic, insec-
ticidal, antifouling, vasorelaxant, and metabolic regulatory activity [16–22]. They have the 
potential to be antibiotics of the future. Moreover, they act as antagonists of human oxy-
tocin receptors [23], inhibitors of platelet aggregation [24], calpain inhibitors against 
stroke [25]. DKPs have relevance in the prevention of cell division [26], cell–cell signaling, 
or quorum sensing [27]. They are useful in smart delivery systems of drugs that have low 
permeability to cross the blood-brain barrier [19]. As a curiosity, DKPs are a hot topic in 
ecological chemistry [28]. Furthermore, DKP-containing compounds are used as catalysts 
or chiral auxiliaries in synthetic organic chemistry, in the formation of alkaloids [29–31]. 
They are an excellent model in theoretical studies on the constrained structural scaffold 
with a relevant pharmacophore [17,32,33]. In the future, cyclic-dipeptide-based com-
pounds will find a wider use in various fields as perfect tools for probing specific proteins 
or metabolites in vivo, or as building blocks for macromolecules. 
Here, we present a comprehensive overview of the recent progress on bio-landscape 
and structural diversity of compounds containing proline-based DKP motif, which are 
exploited as privileged peptidomimetic scaffolds for future innovative drug discovery, 
smart delivery systems, and modern bio-control agents [34–36]. We pay special attention 
to anticancer proline-based DKPs since cancers are main cause of death all over the world, 
with nearly 10 million deaths in 2020 according to the WHO [37]. Therefore, novel, effec-
tive, and safe therapeutics are extremely needed. In this context, the supramolecular struc-
turing and the role of versatile synthons for inspiration in the design of compound librar-
ies in search of ideal ligands with unique proline-DKP motif are also discussed. 
2. Occurence and Biosynthesis of DKPs 
DKP skeleton is observed in micro-species, bacteria, such as Bacillus subtilis, Strepto-
myces, Pseudomonas aeruginosa, or Lactobacillus plantarum [38–40], marine, and terrestrial 
fungi [41] as Aspergillus flavus or Alternaria alternata, and Penicillium, respectively [42,43], 
marine sponges such as Dysidea herbacea, and fragilis [44], or proteobacteria Alcaligenes fae-
calis, algae, lichens, gorgonians, tunicates, plants, or animals venoms. Remarkably, DKPs 
were found in human central nervous system, gastrointestinal tract, or blood [45]. They 
occur in food and beverages, such as pu-erh tea, cocoa, dried bonito, roasted coffee, sake, 
beer, cheese, casein, chicken extract, or stewed beef, giving a special metallic bitter taste 
[13,18,31,32,46–49], but also in culture broths fermented with lactic acid bacteria. Products 
containing both L- and D- proline-based DKPs are common in nature, and their structural 
and biological complexity is highly impressive [50]. As a curiosity, 90% of DKPs in foods 
contain proline [28]. DKPs provide an eco-friendly approach to food and feed 
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preservation [51]. On the other hand, DKP framework is present in drugs, e.g., in ami-
nopenicillin, amoxicillin, ACE inhibitors [52,53] as by-products of spontaneous intramo-
lecular cyclization of the dipeptidyl moiety in active peptide-based substances. Degrada-
tion via DKPs formation is observed during long-term storage. Moreover, DKPs can ap-
pear as a result of chemical peptide synthesis, or hydrolysis of functional peptides and 
proteins [54,55]. The cyclization is facilitated when a proline is present at the second posi-
tion from the N-terminus (i.e., penultimate proline) [55]. 
From the biosynthetic point of view, naturally produced DKPs are known to be ef-
fective and biodegradable, however their production yield is low [56,57]. Laboratory trials 
for DKPs-microbial induction have faced some constraints. Although producing DKPs 
from microorganisms via an expression system is feasible; the optimization is long and 
not a straightforward process [58]. The biosynthesis of DKPs relies mainly on two en-
zymes, non-ribosomal peptide synthetases (NRPs) and tRNA-dependent cyclodipeptide 
synthases (CDPs) [59]. Both enzymes are part of a biosynthetic gene cluster that targets 
DKPs scaffold modifications necessary for the stability of the produced DKPs [60]. Meta-
genomics and next generation sequencing enhanced the biosynthetic gene clusters encod-
ing DKP tailoring enzymes [61]. As reported, the microbial genes responsible for a specific 
secondary metabolite were found to be close to other genes in the dedicated biosynthetic 
gene clusters [62]. Since the genes responsible for DKPs biosynthesis are clustered on the 
microbial chromosome, therefore, the encoding of the biosynthetic genes depends on the 
discovery of a single gene in the pathway. There are approximately 700 known CDPs-
encoding genes clustered with the predicted tailoring genes [9]. Recently, heterologous 
expression, zinc finger nuclease (ZFN) and transcription activator-like effector nuclease 
(TALEN) have been used to edit target genes for secondary metabolite induction in mi-
croorganisms [63]. However, these approaches found some limitations in their efficiency 
and productivity level [64–66]. Thus, clustered regularly interspersed short palindromic 
repeats (CRISPR)/associated protein (Cas) system has been recently used as a new ap-
proach for the biosynthesis of secondary metabolites and for activation of silent biosyn-
thetic gene clusters [67]. CRISPR/Cas system has outmatched other techniques due to its 
possible multi-gene editing and high efficiency. Precisely, type II CRISPR/Cas system has 
been successfully applied for the biosynthesis of secondary metabolites [67]. Previous 
studies reported the use of CRISPR/Cas9 system in the filamentous fungus Trichoderma 
reesei, achieving the homologous recombination of > 93% efficiencies [68]. Similarly, 
Nodvig et al. [69] obtained a genome-edited phenotype by targeting the yA gene in the 
model fungus Aspergillus nidulans. Thus, CRISPR/Cas system could be a potential mecha-
nism for the efficient biosynthesis of DKPs. 
3. DKP Scaffold 
The concept of scaffold is useful in medicinal chemistry and drug design to generate, 
characterize, and compare cores of bio-active substances and their analogs [70]. The scaf-
fold is the main fragment of compound (e.g., ring system) after removal of substituents 
(R-groups) [71,72]. The privileged molecular scaffold is defined as a core structure, which 
forms structurally diverse bio-molecules via introducing different functional groups 
[73,74]. DKPs can play the role of a privileged, multi-functionalized scaffold for the design 
and development of advanced therapeutic agents, drug delivery systems, biomaterials, or 
bio-imaging to mitigate numerous disease conditions, also as for the synthesis of complex 
natural products [74] because of their specific conformational and physico-chemical at-
tributes. DKPs are heterocyclic compounds consisting of two amino acid residues linked 
to a central six-membered lactam ring core with (or without) various substituents, provid-
ing the control of the substituent’s stereochemistry at up to four positions, chiral nature, 
three-dimensionality, and consequently leading to the promotion of the intermolecular H-
bonding interactions with bio-target sites via the corresponding sites of donors and ac-
ceptors [17]. Thus, the rigid DKP core allows either a constrained or flexible behavior of 
amino acids, mimicking preferential peptide conformation [59]. It makes DKP molecules 
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perfect to predicting properties of larger peptides with multiple H-bond acceptors, and 
donor functionality, and multiple sites for the structural elaboration of diverse functional 
groups. These characteristics do not only enable them to bind with high affinity to a large 
variety of receptors and enzymes [32], showing multifarious biological activities, but they 
also allow a more predictable receptor interaction and the development of the drug-like 
physicochemical properties that are required for the multi-objective optimization process 
of transforming lead to a drug product. The general structure for DKP cores can be seen 
in Figure 1. It should be highlighted that even though 2,5-DKPs are the most popular 
[32,75], other two regioisomers, such as 2,3-DKPs, and 2,6-DKPs, are also possible as im-
portant pharmacophores [76]. All isomers can be found in natural sources in the course of 
biochemical synthesis. Interestingly, the first crystal structure of DKP, 2,5-DKP, was re-
ported in 1938 [19,77]. More specifically, 2,5-DKPs are common, naturally occurring pep-
tide derivatives (and are frequently generated as unwanted by-products in the synthesis 
of oligopeptides). The 2,5-DKP core is present in the structure of known drugs, such as 
Tadalafil, phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hyperten-
sion and erectile dysfunction [78–80], Retosiban, an oxytocin antagonist for preterm labor 
[81], Epelsiban, an oxytocin antagonist in premature ejaculation in men [32], Aplaviroc 
against HIV [82], in the vascular disruption, and tubulin-depolymerizing Plinabulin, on 
the basis of marine fungal Halimide, a potential therapeutical drug in lung cancer [83,84], 
and other anticancer natural agents as Ambewelamide, Phenylahistin, Dehydrophenyl-
ahistin [85], Verticillin A [86], antiviral and immunosuppressive Sirodesmin, a type of 
phytotoxin, anti-inflammatory agents, e.g., FR106969 [59], antibacterial Bicyclomycin, 
Brevianamide S, Avrainvillamide [87] or Albonoursin, antifungal Maremycin, mycotoxins 
such as Roquefortine C [22] or Gliotoxin, which is also a potent inducer of apoptotic, and 
necrotic cell death [88,89]. 
 
Figure 1. Structure of 2,3-DKP (on the left), 2,5-DKP (in the middle) and 2,6-DKP (on the right) rings 
as important pharmacophores. 
Thaxtomin A [90], phytotoxin and insecticidal okaramine, and so on. Furthermore, 
2,5-DKPs are present in food, e.g., in fermented olives and beverages. Thus, they have the 
potential to be used in the development of new functional foods [91]. Diverse 2,5-DKPs 
have been discovered from marine habitats (sponges, and microorganisms) in recent years 
[14]. These DKPs have cytotoxic (~36%), antimicrobial (~19%), antiviral (~13%), antioxi-
dant (10%), enzyme inhibition (~5%), and other activities (18%) [14]. 
2,3-DKPs can be found in natural products, e.g., antibiotics, Piperacillin, or Cefopera-
zone [92]. Like 2,5 DKPs, they have been used in medicinal chemistry, for example, against 
diseases wherein platelet agglutination participates [93]. The first synthesis of 2,3-DKP 
was reported by Goulding and Pollard in 1948 [94]. 
2,6-DKPs have been investigated as antiproliferative agents through the inhibition of 
DNA topoisomerase [32,92,95]. They also have other activities, such as anticonvulsant [96] 
or trypanocidal [96–99]. 
Proline-based DKPs have a special characteristic [12]. Proline is a unique amino acid 
due to its specific structure. The DKP nucleus is fused to the pyrrolidine ring, resulting in 
eminent bio-properties, mentioned earlier. Both L- and D-proline, and to a lesser extent 
hydroxyproline-based DKPs, exhibit bio-activity. Moreover, proline cis-trans 
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isomerization play a role inter alia in controlling auto-inhibition of signaling proteins [12]. 
In nature, proline-based DKPs (e.g., cyclo(L-Pro-L-Pro), cyclo(L-His-L-Pro), cyclo(L-Phe-
L-Pro), cyclo(L-Tyr-L-Pro), cyclo(L-Leu-L-Pro), and cyclo(L-Val-L-Pro)) are common, 
which is translated into the structural complexity and impressive bio-activities of this im-
portant class of DKPs [51,91,100–103], which are thoroughly described in the next sub-
section. Interestingly, cyclo(Pro-Pro) is as an archaic precursor in the early evolution of 
life process [5,38]. Notably, many biologically important cyclic peptide sequences, and 
natural products contain multiple proline residues. The ‘proline-rich cyclic structures‘ 
have started gaining the attention of the pharmaceutical industry, but their true potential 
is still very much unknown. Analogs of proline in DKPs should not be overlooked. As an 
example, silaproline exhibits similar conformational properties, but confers higher lipo-
philicity and improved resistance to biodegradation [104]. 
4. Bio-Landscape and Structural Profile of Proline-Based DKPs 
4.1. Anticancer Activity 
4.1.1. Bicyclic Proline-Based DKP with Simple Side Chains 
Bi- and policyclic diketopiperazines containing a proline fragment within the struc-
ture are of a great interest to medical chemists as potential cytotoxic and antineoplastic 
agents. However, in most cases the cytotoxic effect of simple proline-containing bicyclic 
DKPs is quite limited. Ye [105] reported that cyclo (L-Phe-L-Hyp) (1), isolated from man-
grove Streptomyces sp. Q24, inhibits the proliferation of human glioma U87-MG and U251 
cells in at IC50 = 5.8 and 18.6 [μM], respectively (Table 1, entry 1). Cyclo (L-Phe-L-Hyp) (1), 
when tested on the adenocarcinoma HCT-116, the ovarian carcinoma OVCAR-8, and the 
glioblastoma SF-295 cell lines, did not exhibit any significant cytotoxic effect up to the 
concentration of 25 μg/mL (Table 1, entry 1) [106]. Cyclo (L-Leu-L-Hyp) (2) exhibits cyto-
toxic effect on U87-MG and U251 cells lines at IC50 = 14.5 and 29.4 [μM], respectively, while 
its close structural analog cyclo (L-Leu-L-Pro) (3) at IC50 = 1.3 and 19.8 [μM], respectively 
(Table 1, entries 2,3) [105]. Lin [107] reported that cyclo (L-Leu-L-Pro) (3), isolated from 
Streptomyces xiamenensis MCCC 1A01570, evaluated for cytotoxicity against three cancer 
cell lines of ECA-109 (esophageal carcinoma), HeLa-S3 (cervix carcinoma) and PANC-1 
(pancreatic carcinoma) exhibited moderate inhibition effect at 20 μM varying from 14% 
(PANC-1) to 55% (ECA-109) (Table 1, entry 3). Shaala reported [108] that cyclo (L-Leu-L-
Pro) (3), isolated from tunicate-derived actinomycete Streptomyces sp. moderately inhibits 
the proliferation of HCT-116, HepG2 (hepatocellular carcinoma) and MCF-7 (breast can-
cer) cell lines, with values of 16, ≥50, and 30 μg/mL, respectively (Table 1, entry 3). Its 
diastereoisomer, cyclo (D-Leu-L-Pro) (4), evaluated for cytotoxicity against ECA-109, 
HeLa-S3, and PANC-1 exhibited moderate inhibition effect at 20 μM varying from 44% 
(ECA-109) to 55% (PANC-1) [107] (Table 1, entry 4). The cytotoxic effect of cyclo (L-IIe-L-
Pro) (5) was reported in two articles [107,108]. The compound 5 showed limited cell 
growth at 20 μM when tested on ECA-109, HeLa-S3 and PANC-1 cell lines, from 45% 
(HeLa-S3) to 56% (PANC-1) (Table 1, entry 5) [107], while inhibited the proliferation of 
HCT-116, HepG2 and MCF-7 cell lines, with values of 22, ≥50, and 27 μg/mL, respectively 
(Table 1, entry 5) [108]. Its hydroxylated analog, cyclo (L-IIe-L-Hyp) (6), when tested on 
ECA-109, HeLa-S3 and PANC-1 cell lines, inhibited the cell growth at 20 μM from 42% 
(PANC-1) to 54% (ECA-109) (Table 1, entry 6) [107]. Cyclo (4-S-hydroxy-D-Pro-D-Ile) (7) 
was isolated from Australian marine sponge Stelletta sp. and its cytotoxicity was tested on 
human tumour cell lines H460 (lung carcinoma), SF-268 (glioblastoma), MCF-7, HT-29 
(colon adenocarcinoma) and a normal mammalian cell line CHO-K1, derived from ham-
ster ovary. Compound 7 exhibited weak cytotoxic effect on all tested cell line with GI50 
(μM) values varied from 204 (MCF-7) to > 295 (SF-268, CHO-K1) (Table 1, entry 7) [109]. 
Cyclo (L-Phe-L-Pro) (8) exhibited marked cytotoxicity, when tested on HCT-116, OVCAR-
8 and SF-295, with IC50 μg/mL values of 21.4, 18.3, and 16.0, respectively [106]. The cyto-
toxicity observed effect of 8 was stronger than in the case of its hydroxylated derivarive 1 
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(Table 1, entries 1 and 8) [106]. The compound 8 also decreased the cell growth at 20 μM 
when tested on ECA-109, HeLa-S3, and PANC-1 cell lines, from 36% (HeLa-S3) to 50% 
(PANC-1) (Table 1, entry 8) [107]. Two stereoisomers of 8: cyclo (L-Phe-D-Pro) (9) and 
cyclo (D-Phe-D-Pro) (10), as well as their 3-hydroxy analog, Penicicillatide B (11) (Table 1, 
entries 9–11), were isolated from the marine-derived fungus, Penicillium sp. and tested on 
the cytotoxic effect on three cancer cell lines: HCT-116, HepG2 and MCF7 [110]. Of the 
three cell lines tested, HCT116 proved to be the most sensitive to compounds 9–11, with 
the IC50 [μM] values varied from 23.0 for Penicillatide B (11) to 94.0 for cyclo (D-Phe-D-
Pro) (10). Cyclo (D-Phe-D-Pro) (10), a diastereoisomer of cyclo (L-Phe-D-Pro) (9), derived 
from D-Pro instead of L-Pro, exhibited about three times weaker effect then on HCT116 
then 9 (IC50 = 94.0 vs. 38.9 μM), which proves that the configuration of the constituent 
amino acids may have a significant influence on the cytotoxic effect of the tested com-
pound. Cyclo (L-Phe-2-OH-D-Pro) (12), a hydroxylated analog of cyclo (L-Phe-D-Pro) (9) 
was tested on three cancer cell lines: HCT-116, HepG2 and MCF7 (Table 1, entry 12) [108] 
and inhibited the proliferation with IC50 values of 30, ≥50, and 30 μg/mL, respectively. 
Wang reported that cyclo (L-Val-L-Pro) (13) (Table 1, entry 13), could inhibit HeLa cells 
with an inhibition rate of 33.3% at 100 μg/mL [111], while its hydroxylated analog Bacil-
lusamide B (14), (Table 1, entry 14), inhibited the proliferation of HCT-116, HepG2 and 
MCF7 with IC50 values 25, ≥50, and 27 μg/mL, respectively [108]. Brevianamide F, cyclo 
(L-Trp-L-Pro) (15) exhibited marked cytotoxic effect on OVCAR-8 cell line (IC50 = 11.9 
[μg/mL]) (Table 1, entry 15) [106], while its hydroxylated analog cyclo (L-Trp-L-Hyp) (16) 
showed moderate cytotoxic activity with IC50 = 64.34 [μM]) on HL-60 (acute promyelocytic 
leukemia) cell line (Table 1, entry 16) [112]. Cyclo (D-Leu-2-OH-Pro) (17) showed a rather 
weak cytotoxic effect with on HL-60 with IC50 = 98.49 [μM]) (Table 1, entry 16) [112], while 
Penicimutide (18) could inhibit HeLa cells with inhibition rate of 39.4% at 100 μg/mL (Ta-
ble 1, entry 16) [111]. The simplest tricyclic proline-based DKP consists of two proline 
subunits, cyclo (L-Pro-L-Pro) (19) was evaluated for cytotoxicity against ECA-109, HeLa-
S3, and PANC-1 (pancreatic carcinoma) exhibited moderate inhibition effect at 20 μM var-
ying from 20% (ECA-109) to 40% (HeLa-S3) (Table 1, entry 19) [107]. Finally, Vázquez-
Riviera reported [113] that the mixture of cyclo (L-Tyr-L-Pro) (20), cyclo (L-Val-L-Pro) (13), 
and cyclo(L-Phe-L-Pro) (8), isolated from Pseudomonas aeruginosa PAO1, initiated the cell 
death in HeLa and Caco-2 (colorectal adenocarcinoma) cell cultures with IC50 values of 
0.53 and 0.66 mg/mL, respectively. 
Table 1. Bi- and tricyclic proline-based DKP with simple side chains. 










U87-MG 5.8 ± 1.7 [105] 
U251 18.6 ± 0.1 [105] 
HCT-116 >25 1 [106] 
OVCAR-8 >25 1 [106] 
SF-295 >25 1 [106] 
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U87-MG 1.3 ± 0.1 [105] 
U251 19.8 ± 0.8 [105] 
ECA-109  55 2 [107] 
HeLa-S3  41 2 [107] 
PANC-1 14 2 [107] 
HCT-116 16 1 [108] 
HepG2 ≥50 1 [108] 









ECA-109 44 2 [107] 
HeLa-S3 52 2 [107] 
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HeLa-S3 45 2 [107] 
PANC-1 56 2 [107] 
HCT-116 22 1 [108] 
HepG2 ≥50 1 [108] 
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HeLa-S3 47 2 [107] 
































HCT-116 21.4 1 [106] 
OVCAR-8 18.3 1 [106] 
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HCT-116 38.9 [110] 
HepG2 ≥50 [110] 









HCT-116 94.0 [110] 
HepG2 ≥50 [110] 










HCT-116 23.0 [110] 
HepG2 ≥50 [110] 










HCT-116 30 1 [108] 
HepG2 ≥50 1 [108] 









HeLa 33.3 4 [111] 
K562 n.a. [111] 
HL-60 n.a. [111] 
BGC-823 n.a. [111] 









HCT-116 25 1 [108] 
HepG2 ≥50 1 [108] 











HCT-116 >25 1 [106] 
OVCAR-8 11.9 [106] 
SF-295 >25 1 [106] 






























HeLa 39.4 5 [111] 
K562 n.a. [111] 
HL-60 n.a. [111] 
BGC-823 n.a. [111] 










ECA-109 30 2 [107] 
HeLa-S3 40 2 [107] 
PANC-1 34 2 [107] 
1 IC50 [μg/mL]; 2 the inhibitory effect at 20 μM, inhibition rate (%); 3 GI50 (μM); 4 inhbition rate [%] at at 100 μg/mL (510.2 
μM); 5 IR % at at 100 μg/mL (480.8 μM); n.a.—not active. 
4.1.2. Bicyclic Proline-Based DKP Modified with Indole-Based Side Chains 
A number of bicyclic proline-based DKPs, bearing modified indole groups in the side 
chains were obtained from marine organisms. Tryprostatin A (21) and Tryptostatin B (22), 
isolated from marine fungal strain of Aspergillus fumigatus BM939, exhibited moderate in-
hibition effect when tested on H520 (squamous cell carcinoma), MCF7 and PC-3 (prostate 
adenocarcinoma) (Table 2, entries 1,2) [114]. The chemical modifications of Tryprostatins 
structures led to the discovery of diastereoisomer of Tryptostatin B (22), called ds2-TryB 
(23), possessing D-proline instead of L-proline moiety within its structure (Table 2, entry 
3) [114,115]. Ds2-TryB (23) exhibited a very potent inhibitory effect on breast cancer re-
sistance protein (BCRP), which was accompanied by a strong cytotoxic effect observed on 
the panel of 19 cancer cell lines, derived from both solid and blood tumors [116], while 
Tryprostatin A (21) and Tryptostatin B (22) exhibited an only moderate cytotoxic effect on 
H520, MCF7, and PC-3 cell lines at concentrations of 100 μM. The percent cell survival 
observed for ds2-TryB (20) at 100 μM varied from 0% (MCF7) to 0.2% (PC-3), and growth 
inhibition (GI50) in μM was established as 11.9 (H520), 17.0 (MCF7), and 12.3 (PC-3) (Table 
2, entry 3) [115]. Piscarinine A (24) and Piscarinine B (25), isolated from the fungal strain 
of Penicillium piscarium VKM F-691, possess tri- or tetracyclic indole-based heterocycle in 
the side chain of DKP structure, as well as unsaturated, double bond in the proline ring 
(Table 2, entries 4,5) [116]. Initial results suggested that Piscarinine A (24) and Piscarinine 
B (25) exhibited a moderate cytotoxic effect on L929 (murine fibroblasts) and HeLa cell 
lines with IC50 values larger than 50 mg/mL [116]. Further research revealed that out of 36 
tumor cell lines tested [117], LNCAP (prostate carcinoma) cell line seems to be the most 
susceptible to compounds 24 and 25, with IC50 of 2.195 and 1.914 μg/mL, respectively 
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(Table 2, entries 4,5). Notoamide C (26), prenylated indole alkaloids isolated from a ma-
rine-derived fungus, Aspergillus sp., showed moderate cytotoxicity against HeLa and 
L1210 (murine lymphocytic leukemia) cells with IC50 values of 50 and 22 μg/mL, respec-
tively (Table 2, entry 6) [118]. Notoamide M (27) and its ethyl ether—17-O-ethylnotoamide 
M (28), isolated from co-culture of marine-derived fungi Aspergillus sulphureus and Isaria 
feline, significantly decreased colony formation of 22Rv1 (prostate carcinoma) cell line at 
concentrations of 10 μM by 55 and 25%, respectively (Table 2, entries 7–8) [119]. Finally, 
Brevianamide W (29), Brevianamide Q (30), Brevianamide R (31), Brevianamide K (32), 
Brevianamide E (33) were isolated from deep sea derived fungus Aspergillus versicolor 
CXCTD-06-6a and their cytotoxic effect was tested on P388 (murine leukemia), BEL-7402 
(hepatocellular carcinoma) and MOLT-41 (acute lymphoblastic leukemia), but none of 
them showed cytotoxicity against the tested cell lines (Table 2, entries 9–13) [120]. 
Table 2. Bicyclic proline-based DKP modified with indole-based side chains. 











Tryprostatin A (Try A)  
H520 80.1 ± 4.1 1, 79.4 ± 4.2 2 [114] 
MCF7 >100 1, 95.0 ± 4.7 2 [114] 












H520 77.6 ± 3.6 1, 60.5 ± 3.5 2 [114] 
MCF7 88.2 ± 5.8 1, 66.7 ± 5.3 2 [114] 











H520 88.3 ± 8.4 1, 0.1 ± 0.1 2 [114] 
MCF7 73.6 ± 5.3 1, 0.0 ± 0.0 2 [114] 
PC-3 59.3 ± 3.9 1, 0.2 ± 0.0 2 [114] 
H520 11.9 3 [115] 
MCF7 17.0 3 [115] 
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P388 n.a. [120] 
BEL-7402 n.a. [120] 









P388 n.a. [120] 
BEL-7402 n.a. [120] 





P388 n.a. [120] 
BEL-7402 n.a. [120] 









P388 n.a. [120] 
BEL-7402 n.a. [120] 










P388 n.a. [120] 
BEL-7402 n.a. [120] 
MOLT n.a. [120] 
1 cell growth inhibition at 10 μM, percent cell survival; 2 cell growth inhibition at 100 μM, percent cell survival; 3 growth 
inhibition (GI50) in μM; 4 IC50 [mg/mL]; 5 IC50 [μg/mL]; 6 decreased colony formation at concentrations of 10 μM; n.a.—not 
active. 
4.1.3. Tetracyclic Proline-Based DKP 
Drimentidine G (34), tetracyclic, proline-based DKP possessed isopreonoid group, 
was isolated from Streptomyces sp. CHQ-64 [121] and tested for its cytotoxic effect on five 
cell lines: HCT-8 (ileocecal/colorectal adenocarcinoma), Bel-7402, BGC-823 (human papil-
lomavirus-related endocervical adenocarcinoma), A549 (lung carcinoma), A2780 (ovarian 
carcinoma). Compound 34 exhibited promising cytotoxic effect with IC50 values of 2.81 ± 
0.09, 1.38 ± 0.27, >10, 1.01 ± 0.04 and 2.54 ± 0.18 μM, respectively (Table 3, entry 1). In con-
trary to 34, its lactam-methylated analogs, Drimentidine F (35) and Drimentidine H (36) 
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Table 3. Tetracyclic proline-based DKP. 
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BGC-823 MCF-
7 K562  
HL-60 
8.6, 88.1 1 [126] 
8.7, 83.9 1 [126] 
6.0, 80.5 1 [126] 
11.9, 87.7 1 [126] 












SF-268 >100 [127] 












SF-268 >100 [127] 
HepG2 >100 [127] 
1 IR% values at 100 μg/mL. 
Yu reported the isolation of tetracyclic okaramine C (37) and okaramine G (38) from 
coprophilous fungus Aphanoascus fulvescens and tested them for cytotoxic effect on L5178Y 
(mouse lymphoma) cell line (Table 3, entries 4,5) [123]. Compounds 37 and 38 showed 
significant cytotoxicity with IC50 values of 14.7 and 12.8 μM, respectively. Cai described 
novel Okaramines S-U, isolated from Aspergillus taichungensis ZHN-7-07, diprenylated 
Okaramine S (39), monoprenylated Okaramine T (40) and Okaramine U (41) deprived of 
prenyl groups (Table 3, entry 6) [124]. In the cytotoxic evaluation, only diprenylated 
Okaramine S (39) exhibited a promising effect on HL-60 and K562 cell lines with IC50 val-
ues of 0.78 and 22.4 μM, respectively. Roquefortine F (42) and Roquefortine G (43) were 
isolated from a deep ocean sediment derived fungus Penicillium sp. and tested on four cell 
lines: A-549, HL-60, BEL-7402, MOLT-4 (Table 3, entries 7,8) [125]. Roquefortine F (42), the 
more cytotoxic derivative, showed moderate effect with IC50 values of 14.0, 33.6, 13.0, and 
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21.2 μM, respectively, while Roquefortine G (43) with IC50 values of 14.0, 33.6, 13.0, 21.2 
μM, respectively, 42.5, 36.6, >50, and >50 μM, respectively. Fructigenine A (44), Fructi-
genine B (45), Rugulosuvine A (46) as well as N-glycosylated Penicimutanin A (47) and 
Penicimutanin C (48) were isolated from a neomycin-resistant mutant 3-f-31 of Penicillium 
purpurogenum G59 [126]. Compounds 44–48 were tested for cytotoxicty using four cancer 
cell lines: HeLa, BGC-823, MCF-7, K562 and HL-60. While Fructigenine A (44), Fructi-
genine B (45), Rugulosuvine A (46) exhibited rather weak cytotoxic activity on tested cell 
lines (IC50 > 100 μM) (Table 3, entries 9–11), Penicimutanin A (47) and Penicimutanin C 
(48), bearing aglycone attached to the indole ring, showed marked inhibition effect with 
values IC50 [μM] of 10.7 (K562), 6.1 (HL-60), 7.0 (HeLa), 8.3 (BGC-823), and 7.3 (MCF-7) 
for Penicimutanin A (47) and 11.9 (K562), 5.0 (HL-60), 8.6 (HeLa), 8.7 (BGC-823), and 6.0 
(MCF-7) for Penicimutanin C (48) (Table 3, entries 17,18). Two diastereomeric Eurotiumin 
A (49) and Eurotiumin B (50) were isolated from marine-derived fungus Eurotium sp. 
SCSIO F452 and tested for cytotoxicity [127], but did not exhibit a promising effect on SF-
268 and HepG2 cell lines up to 100 μM (Table 3, entries 14,15). 
4.1.4. Penta- and Hexacyclic Proline-Based DKP 
The pentacyclic proline-based DKP are mainly based on series of compounds called 
the Spirotryprostatins and Cyclotryprostatins, analogs of bicyclic Tryprostatins 21–23 (Ta-
ble 2, entries 1,2). Cui reported the isolation of novel mammalian cell cycle inhibitors, Spi-
rotryprostatin A (51) and Spirotryprostatin B (52), produced by Aspergillus fumigatus strain 
[128,129]. These compounds, possessing a spiro indole ring system attached to the tricyclic 
DKP scaffold, inhibited the mammalian cell cycle at G2/M phase with IC50 [μM] values of 
197.5 and 14.0, respectively (Table 4, entries 1,2) [128,129]. Spirotryprostatin B (52) also 
showed cytotoxic activity on K562 (chronic myelogenous leukemia) and HL-60 cell lines 
with the MIC values of 35 μg/mL and 10 μg/mL [129] and IC50 [μM] value of 14.0 for 3Y1 
cell line (rat fibroblasts) [130]. Recently, Spirotryprostatin L (53) and its analog 54 [131] 
were isolated from marine-derived fungus Penicillium brasilianum. The authors observed 
the selective cytotoxicity of 53 and 54 against HL-60 cell line with the IC50 values of 6.0 
and 7.9 μM, respectively (Table 4, entries 3,4). 
Table 4. Penta- and hexacyclic proline-based DKP. 
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PC3 >40 [135] 
DU145 >40 [135] 
LNCaP >40 [135] 
1 complete inhibition of cell cycle progression [μg/mL]; 2 MIC (Minimum Inhibitory Concentration) values for cytotoxicity; 
n.a.—non active. 
Cyclotryprostatin B (55), Cyclotryptostatin F (56), and Cyclotryptostatin G (57) were 
isolated from Penicillium brasilianum together with Spirotryprostatins 53,54 (Table 4, en-
tries 1–3) [131]. These compunds exhibited relatively selective cytotoxic effect when tested 
on breast cancer cell line MCF-7, with IC50 values of 5.1, 7.6, and 10.8 μM, respectively. In 
contrary to Cyclotryprostatins B,F and G (55–57), Cyclotryprostatin E (58), isolated from 
Aspergillus sydowii SCSIO 00305 [132] did not show any cytotoxic effect when tested on 
A549, A375 (human melanoma) and HeLa cell lines (Table 4, entry 8), which may indicate 
that the presence of the prenyl group in the structure of the compound is necessary for 
the appearance of cytotoxic activity. Pentacyclic Versicamide G (59), bearing 11-mem-
bered lactam ring, was isolated from marine-derived fungus Aspergillus versicolor, but was 
not active against HeLa, HCT-116, HL-60 and K562 cell lines (Table 4, entry 9) [133]. To-
gether with Versicamide G (59), six new hexacyclic Versicamides A-F (60–65) (Table 4, 
entries 10–15) were isolated and tested for cytotoxicity against HeLa, HCT-116, HL-60 and 
K562 but significant effect was not observed. Versicamide G (59) was further treated with 
methyl iodide, in the presence of sodium carbonate in tetrahydrofurane, which led to the 
formation of Versicamide H (66) (Table 4, entry 16). In contrary to Versicamides A-G (59–
65), compound 66 surprisingly exhibited moderate cytotoxic effect with IC50 [μM] values 
of 19.4 (HeLa), 17.7 (HCT-116), 8.7 (HL-60) and 22.4 (K562). When tested on the panel of 
18 selected protein kinases, Versicamide H (66) showed effective activity on c-Kit (a trans-
membrane protein that functions as a tyrosine kinase receptor) yielding an inhibitory rate 
of 60% at a final concentration of 10 μM [133]. In 2019, Li reported isolation an identifica-
tion of novel hexacylic asperversiamides I−P from a soil-derived fungus Aspergillus versi-
color [134], and observed that one compound, Asperversiamide I (67), exhibited marked 
cytotoxic activity against HeLa cell line with IC50 = 7.3 μM (Table 4, entry 17). Finally, 
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Speramide B (68) (Table 4, entry 18), a new prenylated indole alkaloid isolated from the 
freshwater-derived fungus Aspergillus ochraceus KM007 [135] was tested for cytotoxicity 
on PC3, DU145 (human prostate carcinoma) and LNCaP cell lines, but did not exhibit any 
effect up to IC50 = 40 μM. 
4.1.5. Hepta-, Polycyclic and Dimeric Proline-Based DKP 
Heptacyclic Speramide A (69), isolated together with Speramide B (68), from fungus 
Aspergillus ochraceus KM007 [135] was also tested for cytotoxicity on PC3, DU145 and 
LNCaP, but also did not exhibit any effect up to IC50 = 40 μM (Table 5, entry 1). Heptacyclic 
Stephacidin A (70) was isolated from Aspergillus ochraceus WC76466 strain [136] and tested 
on ten cancer and one reference non-cancerous cell lines: PC3 (prostate, testosterone-in-
dependent), LNCaP (prostate testosterone-sensitive), A2780 (ovarian parental), 
A2780/DDP (ovarian mutp53/bcl2+), A2780/Tax (ovarian taxol-resistant), HCT116 (colon 
parental), HCT116/mdr+ (overexpress mdr+), HCT116/topo (colon resistant to etoposide), 
MCF-7 (breast estradiol-sensitive), SKBR3 (breast estradiol-independent), and reference 
LX-1 (non-cancerous, human hepatic stellate cell line). Compound 70 exhibited a strong 
cytotoxic effect with IC50 [μM] values varied from 1.00 (LNCaP) to 13.10 (HCT116/topo) 
(Table 5, entry 2). Drimentine I (71), isolated from Streptomyces sp. CHQ-64 strain, was 
evaluated in vitro for its cytotoxicity against two human tumor cell lines (A549 and HeLa) 
and exhibited weak activity against human cervical carcinoma cell line HeLa, with IC50 
values of 16.73 μM (Table 5, entry 3) [137]. Gartryprostatin A (72) and Gartryprostatin B 
(73) were isolated and identified as secondary metabolites of Aspergillus sp. GZWMJZ-
258, an endophyte of the medicinal and edible plant Garcinia multiflora [138]. Compounds 
72 and 73 were tested for cytotoxic effect on four cancer cell lines: MV4-11, K562, HL-60, 
and A549 and exhibited selective cytotoxic effect against leukemic MV4-11 cell line with 
IC50 values of 7.2 μM and 10.0 μM, respectively (Table 5, entries 4,5). (+)-Avrainvillamide 
(74), isolated from the fermentation broth of Aspergillus ochraceus [87], turned out to be a 
potent inhibitor of tumor-associated protein—nucleoplasmin [139,140] overexpressed in 
many human tumors, exhibiting strong cytotoxic effect against HeLa (IC90 [μg/mL] = 1.1) 
[87], T-47D (breast cancer, GI50 [μM] = 0.33), and LNCaP (GI50 [μM] = 0.42) cell lines [139] 
(Table 5, entry 6). Its enatiomer 75 exhibited a weaker, but still potent cytotoxic effect, 
when tested on T-47D and LNCaP cell lines with GI50 [μM] values of = 0.91 and 1.4, re-
spectively (Table 5, entry 7) [140]. (+)-Avrainvillamide (74) was further investigated as a 
potential antileukemic agent [140] and tested on five acute myeloid leukemia (AML) cell 
lines: NB4, HL-60, MV4-11, OCI-AML3, and Molm-13 giving IC50 [μM] values from 1.1 
(NB4) to 0.078 (Molm-13). Waikikiamide A (76) and Waikikiamide B (77) were isolated 
from a Hawaiian marine fungal strain Aspergillus sp. FM242. Their cytotoxic effect was 
evaluated on four cancer cell lines HT1080, (fibrosarcoma), PC3, Jurkat (acute T cell leu-
kemia), and A2780S (human ovarian cancer) [141]. 
Table 5. Hepta-, polycyclic and dimeric proline-based DKP. 
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WIN 64821 (82) 
HT-29 >20 [143] 
A375 >20 [143] 
MCF-7 >20 [143] 
HepG2 >20 [143] 
1 Inhibition rate at 10 μM; 2 IC90 [μg/mL]; 3 GI50 [μM]; n.a.—not active. 
The more potent Waikikiamide A (76) exhibited activity with IC50 [μM] values from 
0.519 (HT1080) to 1.855 (PC3) (Table 5, entry 8), while Waikikiamide B (77) from 1.127 
(A2780S) to 1.805 (PC3) (Table 5, entry 9). Dimeric Stephacidin B (78) was isolated together 
with Stephacidin A (70) from Aspergillus ochraceus WC76466 strain [136] and tested on a 
similar panel of ten cancer and one reference non-cancerous cell lines: PC3, LNCaP, 
A2780, A2780/DDP, A2780/Tax, HCT116, HCT116/mdr+, HCT116/topo, MCF-7, SKBR3 
and LX-1. Compound 78 exhibited stronger cytotoxic effect then compound 70 with IC50 
[μM] values varied from 0.06 (LNCaP) to 0.46 (HCT116, HCT116/mdr+) (Table 5, entry 
10). Nandaseseazine A (79) Naseseazine B (80) were obtained from Streptomyces sp. (CMB-
MQ030) isolated from a Fijian marine sediment and tested for cytotoxicity on four cancer 
cell lines: AGS (gastric adenocarcinoma), SH-SY5Y (neuroblastoma), TF-1 (erythroleuke-
mia) and HT-29 (colorectal adenocarcinoma) but were found to be rather non-toxic com-
pounds [142] (Table 5, entries 11,12). Asperflocin (81), an asymmetric diketopiperazine 
dimer from the sponge-associated fungus Aspergillus versicolor 16F-11, and its diastere-
omer WIN 64821 (82) were evaluated as potential anticancer agents on the panel of four 
cancer cell lines; HT-29, A375, MCF-7, and HepG2, but only Asperflocin (81) exhibited 
moderate selectivity against A375 cell line with IC50 [μM] value of 10.29 ± 2.37 (Table 5, 
entries 13,14) [143]. 
4.1.6. Sulfur-Containing Proline-Based DKPs 
There are numerous examples of various proline-based diketopiperazine alkaloids 
which have in their structure from one to four sulfur atoms in the form of sulfide or pol-
ysulfide bridges or thiomethoxy groups. The influence of the presence of sulfur atoms as 
well as the type of sulfur-containing functional groups on biological properties of proline-
based DKPs is best seen on the example of the tricyclic gliotoxin (83) and its analogs [144]. 
Gliotoxin (83), possessing tricyclic structure with disulfide bond, as well as its acetylated 
derivative—Acetylgliotoxin (84) are strong cytotoxic agents when tested on cancer cell 
lines: SF-268, MCF-7, NCI-H460, and HepG-2 with IC50 [μM] varied from 0.08 (MCF-7) to 
0.25 (SF-268, NCI-H460) for 83 and from 0.22 (MCF-7) to 0.49 (HepG-2) (Table 6, entries 
1,2). 6-deoxy-5a,6-didehydrogliotoxin (85) also possessing disulfide bond within its struc-
ture, also exhibited significantly but slightly weaker cytotoxicity with IC50 [μM] varied 
from 0.68 (MCF-7) to 1.52 (HepG-2) [144] (Table 6, entry 3). Bisdethiobis(methylthio)glio-
toxin (86), 6-acetylbisdethiobis(methylthio)gliotoxin (87) and Dichotocejpin A (88), bear-
ing two (86,87) or one (88) thiomethoxy groups instead of disulfide bond, exhibited mark-
edly weaker (87,88) or no (86) cytotoxic effect on tested cell lines [144] (Table 6, entries 4–
6). Structural analog of Gliotoxin (83) devoid of sulfur groups, Dichotocejpin B (89) lacking 
any activity on above cell lines tested (Table 6, entry 7). From these results it can be gen-
erally assumed that the compounds with the disulfide bridge show the greatest cytotoxic 
effect, the compounds with thiomethoxyl groups instead of the disulfide bridge show a 
weaker effect, and the compounds devoid of sulfur groups have the weakest cytotoxic 
effect in the whole series of compounds. Sun [145] reported the isolation and identification 
of gliotoxin and its analogs from a marine-derived fungus, Penicillium sp. including 83, 
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85, 86, bis(dethio)-10a-methylthio-3a-deoxy-3,3a-didehydrogliotoxin (90), bis(dethio)bis-
(methylthio)-5a,6-didehydrogliotoxin (91), 5a,6-didehydrogliotoxin (92) and Gliotoxin G 
(93) and tested them for cytotoxic effect on P388 cell line (Table 6, entries 1,3,4,8–11). He 
found that Gliotoxin G (93), possessing tetrasulfide bond, was the most active of the tested 
compounds, exceeding its cytotoxicity of the reference compound gliotoxin (83) (IC50 [μM] 
= 0.020 vs. 0.024, Table 6, entries 1,11). On the other hand, bis(dethio)-10a-methylthio-3a-
deoxy-3,3a-didehydrogliotoxin (90) showed the weakest cytotoxic effect on the line tested 
with IC50 [μM] value of 3.4 (Table 6, entry 8). A series of gliotoxin derivatives including 
83, 84, 86, 87 together with reduced gliotoxin (94) and 6-deoxy-bis(dethio)bis-(methyl-
thio)-5a,6-didehydrogliotoxin (95) were isolated from the marine fungus Neosartorya 
pseudofischeri [146] and tested for cytotoxic effect on three cell lines: HEK293 (human em-
bryonic kidney), HCT-116, and RKO (a poorly differentiated colon carcinoma cell line). 
Compounds 87 and 95 proved to be inactive (Table 6, entries 5,13), compound 86 exhibited 
moderate inhibition effect with IC50 [μM] of 16.39 (HEK293), 8.59 (HCT-116), and 10.32 
(RKO) (Table 6, entry 4). Compounds 83, 84 and 94 showed the strongest cytotoxic effect 
(Table 6, entries 1,2,12), and reduced gliotoxin (94) showed slightly more potent cytotoxi-
city and selectivity than the reference compound gliotoxin (83) (IC50 [μM] = 1.58 vs. 1.26 
for HEK293, 1.24 vs. 0.46 for HCT-116 and 0.8 vs. 0.41 for RKO). Compounds 83 and 91 
were isolated by Zhao from Aspergillus fumigatus strain [147], who reported the IC50 
[μg/mL] values for tsFT210 cell line of 0.15 and 89, respectively (Table 6, entries 1,9). Wang 
observed the cytotoxic effect of 83, 86 and 91 on U-937 (histiocytic lymphoma) and PC-3 
cell lines [148] and reported IC50 [μM] values for U-937 cell line of 0.20 (83), 0.52 (86) and 
>100 (91) (Table 6, entries 1,4,9). The PC-3 cell line turned out to be more resistant to the 
tested compounds, for which the IC values were 0.39 (83), 15.8 (86) and >100 (91), respec-
tively [148] (Table 6, entries 1,4,9). Zhao reported [149] that 3-dehydroxymethylbisdethio-
3,10a-bis(methylthio)gliotoxin (96) and two other gliotoxin analogs 86 and 91 could inhibit 
B16 cancer cell line with inhibitory rate of 86%, 82%, 78%, respectively, at the concentra-
tion of 500 μg/mL (Table 6, entries 4,9,14). Coculture of a mine drainage-derived Sphingo-
monas bacterial strain, KMK-001, and a mine drainage-derived Aspergillus fumigatus fungal 
strain, KMC-901, resulted in isolation of two novel analogs of gliotoxin (83), glionitrin A 
(97) [150] glionitrin B (98) [151], possessing aromatic nitro group within their structures 
(Table 6, entries 15,16). Glionitrin A (97) was tested for cytotoxic effect against six human 
cancer cell lines, it showed submicromolar inhibition of cell proliferation in the HCT-116, 
A549, AGS (gastric adenocarcinoma), and DU145 cell lines (IC50 = 0.82, 0.55, 0.45, and 0.24 
μM, respectively). Glionitrin A (97) showed relatively weaker inhibition of the cell prolif-
eration of the MCF-7 and HepG2 cell lines (IC50 = 2.0 and 2.3 μM, respectively) [150]. In 
contrast to glionitrin A (97), glionitrin B (98) was not cytotoxic against the human prostate 
cancer cell line DU145 [151]. However, compound 98 caused suppression of DU145 cell 
invasion, producing 46% inhibition at 60 μM [151]. Phomazine B (99), a novel gliotoxin 
(83) analog was isolated from the marine-derived fungus Phoma sp. OUCMDZ-1847 [152]. 
Compound 99 showed a rather moderate/weak cytotoxic effect when tested on HL-60, 
HCT-116, A549, K562, MGC-803 (human gastric cancer) cell lines with the highest cyto-
toxicity on MGC-803 (IC50 = 8.5 μM) (Table 6, entries 17). As gliotoxin (83) has promising 
cytotoxic properties and a broad spectrum of activity against various types and types of 
cancer, its structure was also an inspiration for the design and synthesis of a number of 
bicyclic analogs with a disulfide bridge that showed significant cytotoxic effects [153]. 
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Table 6. Sulfur-containing proline-based DKPs. 
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0.281 ± 0.022 
0.158 ± 0.070 
0.223 ± 0.099 






1 IC50 [μg/mL]; 2 inhibitory rate at the concentration of 500 μg/mL; n.a.—not active; n.t.—not tested. 
A series of five, tetracyclic, proline-based DKPs, containing disulphide and trisul-
phide bridges, were isolated by Wang from deep sea-derived fungus Acrostalagmus luteo-
albus SCSIO F457 [154]. Luteoalbusin A (100), Luteoalbusin B (101), T988A (102), Glio-
cladine C (103) and Gliocladine D (104) were tested for cytotoxicity on four cancer cell 
lines: SF-268, MCF-7, NCI-H460, and HepG-2, exhibiting significant effect, where MCF-7 
cell line proved to be the most sensitive and NCI-H460 line the most resistant to the com-
pounds tested (Table 6, entries 18–22). The highest cytotoxicity was observed for Luteoal-
busin A (100) with IC50 [μM] values of 0.46 (SF-268), 0.23 (MCF-7), 1.15 (NCI-H460), and 
0.91 (HepG-2), while the weakest cytotoxicity was for Gliocladine D (104) with IC50 [μM] 
values of 2.49 (SF-268), 0.65 (MCF-7), 17.78 (NCI-H460), and 2.03 (HepG-2). Tetracyclic, 
chlorinated Sporidesmin A (105) was isolated from a Freshwater Delitschia sp. [155] and 
was evaluated against the African American prostate cancer cell line (E006AA-hT) under 
hypoxic conditions giving IC50 [μM] value of 2.5 (Table 6, entry 23). A series of six, penta-
cyclic, proline-based DKPs, containing disulphide bridge were isolated by Meng from 
Penicillium brocae MA-231, an endophytic fungus derived from the marine mangrove plant 
Avicennia marina [156]. Brocazines A-F (106–111) were evaluated for possible cytotoxic ef-
fect using nine cancer cell lines: Du145, HeLa, HepG2, MCF-7, NCI-H460, SGC-7901 (gas-
tric cancer), SW1990 (pancreatic adenocarcinoma), SW480 (colon adenocarcinoma), and 
U251. The authors reported that two compounds, Brocazine C (108) and Brocazine D (109), 
did not exhibit significant cytotoxic activity against the tested cancer cell lines with IC50 
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values greater than 20 μM (Table 6, entries 26, 27). Brocazine A (106) exhibited the cyto-
toxic effect in the range of 2.0 (SW480)—6.8 (HeLa) (Table 6, entry 24), Brocazine B (107) 
in the range of 1.2 (SW480)—6.4 (SW1990) (Table 6, entry 25), Brocazine E (110) in the 
range of 2.1 (SW1990)—12.4 (NCI-H460) (Table 6, entry 28) and Brocazine F (111) in the 
range of 0.89 (NCI-H460)—8.0 (SGC-7901) (Table 6, entry 29). Pentacyclic, proline-based 
DKPs, possessing disulphide bridge or thiomethoxy groups were isolated by Kong from 
the marine-derived fungus Phoma sp. OUCMDZ-1847 [152]. Epicorazine A (112), Epicora-
zine B (113), Epicorazine C (114), and Exserohilone A (115) were tested for cytotoxic effect 
against five cancer cell lines: HL-60, HCT-116, A549, K562, and MGC-803 (Table 6, entries 
31–34). The authors found that Epicorazine A (112) turned out to be the most cytotoxic 
from the compounds tested with IC50 values of 0.05 (HL-60), 0.33 (HCT-116), 2.3 (A549), 
1.5 (K562), and 2.7 μM (MGC-803) (Table 6, entry 31), and HL-60 cell line was the most 
susceptible from the lines used in the research. Brocazine G (116), Spirobrocazine A (117), 
and Spirobrocazine B (118) were isolated from the mangrove-derived endophytic fungus 
Penicillium brocae MA-231 and tested for cytotoxicity against sensitive and cisplatin-re-
sistant human ovarian cancer cell lines A2780 and A2780 CisR (Table 6, entries 35–37) 
[157], whereas Spirobrocazine A (117) and Spirobrocazine B (118) did not exhibit any ac-
tivity, Brocazine G (116) showed strong activity not only to A2780 but also to A2780 CisR 
cells, with IC50 values of 0.664 and 0.661 μM, respectively, stronger than that of cisplatin 
used as a positive control. 5′-Hydroxy-6′-ene-epicoccin G (119), 7-methoxy-7′-hydroxyep-
icoccin G (120), 8′-acetoxyepicoccin D (121), 7′-demethoxyrostratin C (122), Epicoccin E 
(123), Epicoccin G (124), and Rostracin C (124) were isolated by Chi from the deep sea-
derived fungus Epicoccum nigrum SD-388 and tested for cytotoxicity against Huh7.5 liver 
tumor cells (Table 6, entries 38–44) [158]. Compounds 119–121, 123, and 124 turn out to be 
completely inactive, while 7′-demethoxyrostratin C (122) and Rostracin C (125) showed 
marked activity with IC50 values of 9.52 and 4.00 μM, respectively, but were also toxic to 
human normal liver LO2 cell line. The authors suggested that disulfide bridge is likely 
required for cytotoxic activity. Chinworrungsee reported isolation and identification of 
three novel pentacyclic compounds 126–128 obtained from seed fungus Menisporopsis the-
obromae BCC 3975, which were tested against three cancer cell lines: KB (papilloma), BC-
1 and NCI-H187 (lung carcinoma) (Table 6, entries 45–47) [159]. Compounds 126–128 ex-
hibited rather weak cytotoxic effect with the highest IC50 values for 126 of 22.9 (NCI-H187) 
and 29.2 μM (BC-1) and for 127 of 20.3 μM (NCI-H187). A number of dimeric, sulfur-
containing DKPs were isolated from fungal sources including Cristazine (129), found in 
the mudflat-sediment-derived fungus Chaetomium cristatum [160]. Cristazine (129), exhib-
ited cytotoxic effect on HeLa and A451 with IC50 values of 0.5 μM, respectively, induced 
apoptosis via the death receptor pathway [160,161] (Table 6, entry 48). Chaetocin (130) is 
a dimeric sulfur-containing DKPs, which exhibited a wide range of cytotoxic effect on 
both solid and blood tumors [169,170]. Lai observed that Chaetocin (130) induced differ-
entiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid 
leukemia cells HL-60, U937 and KG-1a [162]. He reported IC50 values of 0.153 (HL-60), 
0.096 (U937) and 0.103 (KG-1a) (Table 6, entry 49). A series of sulfur-containing, dimeric 
DKP were isolated from Bionectriaceae cultures MSX 64546 and MSX 59553, including 
Verticillin A (131), Verticillin H (132), Sch 52900 (133), Sch 52901 (134), Gliocladicillin A 
(135), Gliocladicillin C (136), and 11′-Deoxyverticillin (137) [163]. All compounds (131–
138) were evaluated for cytotoxicity against a panel of human cancer cell lines (HT-29, 
H460, SF-268, MCF-7 and MDAMB-435), displaying IC50 values ranging from 1.2 mM to 
10 nM (Table 6, entries 50–57). Verticillin A (131), Verticillin H (132), and their ester deriv-
atives also exhibited strong cytotoxic effect on MDA-MB-231 and OVCAR3 cell lines (Ta-
ble 6, entries 50–51), in the few cases, some of the ester derivatives showed higher cyto-
toxicity than the parent compounds [164]. Further studies proved the effectiveness of Ver-
ticillin A (131) in human gastric (AGS) [165], cervical (HeLa) [165], and ovarian cancer 
[166] cells lines (Table 6, entry 50). 11′-Deoxyverticillin (137) and 11,11′-dideoxyverticillin 
(138) were also very active against HCT-116 human colon carcinoma (IC50 = 0.030 μM/mL) 
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(Table 6, entries 56–57) [167] and 11,11′-dideoxyverticillin (138) also showed strong cyto-
toxic effect against human breast adenocarcinoma MDAMB-468, MCF-7, MDA-MB-435, 
and MDA-MB-231 cell lines with IC50 values of 0.281, 0.158, 0.223, and 0.138 μM, respec-
tively [168] (Table 6, entry 57). 
Except of the direct cytotoxic effect, there are some other reports suggesting useful-
ness of proline-based DKPs in the treatment of cancer and supporting anticancer therapy. 
Yu reported [171] that several pentacyclic, hexacyclic, or dimeric proline-based DKPs 
could be potent inhbitors of BRD4 protein (Bromodomain-containing protein 4), very of-
ten expressed in various types of tumors. Fumitremorgin C (139) and their analogs are 
selective and potent inhibitors of the multidrug-resistance protein (BCRP/ABCG2) that 
mediated resistance to chemotherapeutics [172]. Octacyclic proline-based DKP, Nocardi-
oazine A (140) proved to be a noncytotoxic inhibitor of the membrane protein efflux pump 
P-glycoprotein, reversing doxorubicin resistance in multidrug resistant colon cancer cells 
[173]. Gliotoxin analogs could also act as non-histone arginine methyltransferase inhibi-
tors [174]. Finally, Leptosins, proline 2,5-DKP derivatives, isolated from marine fungus 
Leptoshaeria, play a role of antitumor agents inhibiting DNA topoisomerases [175]. 
4.2. Other Bio-Activities 
In the following sub-sections, key issues are only discussed briefly since a growing 
potential in terms of broad spectrum bio-activities of proline-based DKPs have been ob-
served only recently. 
4.2.1. Neuroprotection 
Neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease 
(PD), and amyotrophic lateral sclerosis (ALS) are age-dependent multifactorial patholo-
gies [19] with various etiopathogenetic sources, but sharing common pathogenic mecha-
nisms: neuroinflammation, oxidative and ER stress; all characterized by neuronal death 
and degeneration leading to a progressive functional decline. There is no currently avail-
able treatment to cure any of those diseases with only symptomatic or slowing down the 
progress of mental regression is offered.  
Therefore, there is a demand for the new class of pharmaceutics providing the neu-
roprotection and preventing neurons damage. Neurodegenerative diseases could be 
treated DKP, and their analogs, as they can cross the BBB, because of their unique cyclic 
structure, and inhibit neuronal degeneration due to their good pharmacokinetic profile 
and long-lasting neuroprotection. There are mainly two classes of DKP: 1., the TRH-re-
lated and 2., unsaturated compounds, proposed recently as potential drug candidates pos-
sessing remarkable neuroprotective profile. 
TRH-Related DKP 
Naturally occurring hormone, thyrotropin-releasing hormone (TRH), L-pyroglu-
tamyl-L-histidyl-L-prolineamide, was the first characterised as playing neuromodulatory 
role within the central nervous system (CNS) with noticing its rapid enzymatic degrada-
tion, what is a big disadvantage for clinical use [176,177]. Therefore, during the last two 
decades researchers have focused on the cyclic derivatization of the linear TRH peptides, 
naturally occurring and synthetic [19] with the most investigated cyclo(His-Pro), (CHP), 
produced by the metabolism of TRH as regulatory agent mediating brain activities 
[176,177]. CHP is ubiquitous in the cerebrospinal fluid (CSF), blood, and several other 
body fluids [178] playing important roles in pain awareness, body core temperature, food 
intake, and modulating prolactin secretion, acting as an endocrine effector. There is a cor-
relation between the decrease CHP level and increased age of patients reaching a value in 
adulthood of 300 pg/mL in adult age, while for the preterm babies it is 1909 pg/mL. CHP 
and CHP-like compounds, when increased the presence in CSF, they can improve cogni-
tive function and enhance neurological recovery after trauma due to their molecular 
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mechanisms of neuroprotection to be related to apoptosis and necrosis; DNA repair; oxi-
dative stress; ER stress and unfolded protein response; mitochondrial energy metabolism; 
together with immunity pathways. Additionally, CHP was found to protect neurons from 
cytotoxicity induced by salsolinol, a metabolite of L-DOPA linked to Parkinson. CHP was 
proven to inhibit the pro-inflammator NF-kappaB pathway and its isomers were tested 
against neuropathological conditions showing an ameliorating potential via elevating 
METAP2 (responsible for promoting cell proliferation in SH-SY5Y neuroblastoma cells 
and for exhibiting immune-modulatory activity) expression decreased by Abeta 1–42 
[179]. Moreover, the CHP isomer exhibited noncytotoxic and non-mutagenic features in 
cultured human blood cells and DKP derivatives are promising therapeutics against neu-
rodegeneration-related pathologies [19,179]. They are multipotent anti-Alzheimer drug 
candidates [179,180]. They also are promising in the treatment of other neurodegenerative 
diseases, such as amyotrophic lateral sclerosis (ALS, mentioned previously) [179]. The 
TRH-related DKPs are reported to prevent or reduce both necrotic and apoptotic cell 
death, they were tested in diverse in vitro models to present significantly improved cog-
nitive and motor outcomes and to reduce lesion volumes following traumatic brain injury. 
From all the bio-evaluations reported in the literature, it could be concluded that the pro-
line residue is a structural element contributing significantly to the DKPs biopotency [19]. 
Unsaturated DKPs 
DKPs consisting of unsaturated units possess the ability to enhance somatosensory-
motor function and long-term histological outcome to exhibit a significant radical scav-
enging activity. The naturally occurring and synthetic DHP derivatives are comprehen-
sively described by Pinnen and colleagues in their mini-review [19]. They concluded that 
in those DKP scaffolds, the unsaturated motifs play a pivotal role in the protective and 
reparative properties of these DKPs, suggesting that the increase of bioactivity is strictly 
related to the presence of unsaturated groups in the DKP and such design can contribute 
significantly to the development of the potential therapeutic intervention in neurodegen-
erative diseases. 
Other DKPs 
The cyclic dipeptides not structurally related to TRH or with unsaturated fragment 
have also been shown to exhibit neuroprotective and nootropic properties. The first ex-
ample is cyclo(Leu-Gly), the cyclic analog of H-Pro-Leu-Gly-NH2, the C-terminal neuro-
hypophyseal tripeptide of oxytocin, reducing the blockade of memory induced by puro-
mycin, a protein synthesis inhibiting drug which can impair memory processes. The sec-
ond example is cyclo(Pro-Gly) that was found to reduce motor neuron death induced by 
glutamate, probably due to the presence of neuroprotective Gly in the structure and po-
tentially slowing down the progression of ALS [181]. 
Cyclo(Pro-Gly) is the only, apart from cyclo(His-Pro), cyclic dipeptide in the central 
nervous system. It can be derived from glycine-proline-glutamate. It has anxiolytic activ-
ity [181]. It is an endogenous prototype of Piracetam (derivative of gamma-aminobutyric 
acid), a nootropic drug. Cyclo(Pro-Gly) and its analog cyclo-L-glycyl-L-2-allylproline are 
neuroprotective after ischaemic brain injury [182]. Moreover, it has the antinociceptive 
effect that is mediated through the interaction with opioid system, with fewer side effects 
[183]. Cyclic glycyl proline compounds are promising in the treatment of Pitt Hopkins 
Syndrome, a rare, genetic neurological disorder [184], for which there is no cure so far. 
Moreover, cyclo(Pro-Gly) is a nature nutrient of the blackcurrant anthocyanins. It can im-
prove the function of insulin-like growth factor-1, in Parkinson disease [185,186]. In the 
latter case, cyclo-L-glycyl-L-2-allylproline has relevance as well [187]. Interestingly, cy-
clo(Gly-Pro) is a major bioactive component of raksi, an ethnic beverage, considered as a 
remedy for every possible disorder related to high-altitude sicknesses. This cyclo-dipep-
tide, reported earlier as antibiotic, is also a potential antioxidant, reported as promising 
anti-inflammatory, pain reliever, neuroprotective, and antinociceptive [27,188,189]. 
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Cyclo(L-His-L-Pro) and cyclo(L-Trp-L-Pro) are anti-depressants and learning motivation 
improvers [190].  
The derivatives of gliotoxin, without a disulfide bridge, are a new promising class of 
opioid antagonists with neuroprotective properties. Other DKP-based compounds are in-
hibitors of opioid receptors as well. DKPs show clinical implication in neurological recov-
ery after a traumatic brain or spinal cord injuries [191–193].  
2,6-DKPs display a broad anticonvulsant activity in epilepsy, a major neurological 
disorder, exhibiting a broad spectrum of seizure-suppressing effect. Notably, traditional 
antiseizure drugs lead to severe side effects and drug–drug interactions caused by enzyme 
induction. Keeping in mind the drug-resistance as growing problem, DKPs are a good 
promise for the need of either more effective, safer, or ‘disease modifying drugs‘ that in-
hibit or reverse the progression of the sickness [96,194]. 
Mode of Actions 
Due to their heterocyclic structure, DKPs possess high biostability against the prote-
olysis and bioavailability for the active intestinal absorption and crossing the blood-brain 
barrier (BBB), both challenging targets for natural linear peptides. DKPs can reduce oxi-
dative and ER stress as well as inflammation, the main culprits of several neurological 
disorders. Some of DKPs can act in the bacterial quorum sensing (QS), therefore they can 
influence the gut microbiome regulation, quite important in any clinical dysregulations, 
including neuropathology. This section is divided into four components, each presenting 
the individual aspect of the DKP properties. 
The Blood-Brain Barrier Transporters 
The drugs delivery to the specific target sites is a challenge. Biological barriers such 
as blood brain barrier (BBB) prevent the passage of nearly all drugs to the brain [195]. 
Most of the DKPs have an ability to cross the BBB [74,196]. More specifically, the ring 
structure allows permeability, as well as protects against proteolytic degradation. Thus, 
DKPs are perfect candidates for new therapeutics to treat brain diseases by oral admin-
istration [19,197]. The DKP-derived template has been also investigated as a brain shuttle 
for the delivery of medicinal agents with limited ability to cross the BBB, bypassing the 
limited bioavailability of several drugs [19,196]. 
Antioxidant Activity 
DKPs are a source of natural antioxidants [198–200] due to their significant radical 
scavenging ability. The spiro-anthronopyranoid DKPs, namely variecolortides, isolated 
from the mycelia of the halotolerant fungal strain Aspergillus variecolor, exhibit antioxidant 
activity [4]. The DKPs with the DOPA catechol entity [201], such as cyclo(His-Pro), CHP 
[176] were isolated from Bacillus sp. N strain [202], as an example. CHP reduces oxidative 
and endoplasmic reticulum stress by increasing antioxidant capacity in the potential treat-
ment of neurodegenerative diseases [179]. The treatment with CHP isomers provided sig-
nificant positive oxidative alterations via reducing oxidant status and supporting antiox-
idant capacity in the cellular AD model by protecting rat insulinoma cells (RINm5F) from 
streptozotocin (STZ)-induced in vitro cytotoxicity by minimizing of nitric oxide (NO) pro-
duction and lipid peroxidation [179]. The proline structural element in CHP is responsible 
for its neuroprotective, nootropic, and cognitive-enhancing properties due to its specific 
conformation [203,204]. The DKP compounds enhance memory function and the incorpo-
ration of the proline in the 2,3- or 2,5-DKP skeleton presents a crucial aspect of neuropro-
tective action of theses cyclic peptides [19]. They are multipotent anti-Alzheimer drug 
candidates [179,180]. They also are promising in the treatment of other neurodegenerative 
diseases, such as ALS [179].  
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DKP and Gut Microbiota 
DKP and their analogs have been isolated from Gram-positive and Gram-negative 
marine bacteria and identified as a promising source of bioactive compounds with poten-
tial pharmacologic activity. These cyclic dipeptides are involved in the bacterial quorum 
sensing (QS), a cell-to-cell communication system based on the production, secretion, and 
detection of signals, QS effectors, that contain a family-defining cyclic dipeptide core/scaf-
fold and are produced by proteobacterial species as well as by humans [205]. Therefore, 
they could play a crucial role in gut dysbiosis, a primary factor behind various gastroin-
testinal disorders causing increased intestinal and BBB permeability via microbiota-gut-
brain axis. Such uncontrolled accumulation of misfolded proteins can facilitate the axonal 
damage and neuronal demyelination in the pathogenesis of neurodegenerative disorders 
such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and amyotrophic lat-
eral sclerosis [206]. 
Protein–protein Interaction Mechanism 
The role of DKP derivatives can be especially important in relation to ‘difficult tar-
gets‘ such as protein–protein interactions. More specifically, DKP scaffolds can play a lead 
role as antiprion agents [195]. Prion diseases, allo known as transmissible spongiform en-
cephalopathies, are fatal infectious and neurodegenerative disorders, while effective 
drugs are lacking. Both prion and Alzheimer’s diseases are protein misfolding disorders. 
The interplay of prion and Alzheimer’s diseases, which cause dementia in over 40 milion 
people all over the world, revealed an urgent need for antiprion treatment. The progres-
sion of the disease is caused by the conformational change of the prion protein, from al-
pha-helical to beta-sheeted form, forming amyloid aggregates. A planar conformation of 
DKP core is the main determinant for this kind of bio-activity [207]. DKPs can modulate 
protein–protein interactions. They can optimize the desired anti-aggregating properties 
[195]. 
4.2.2. Metalloproteinase Inhibitors 
DKPs, such as cyclo(His-Pro), are important agents in terms of matrix metallopro-
teinases (and collagenase inhibitors), zinc-based enzymes, engaged in the degradation 
and remodeling of the extracellular matrix, mainly with regard to cancer or arthritis 
[32,208], but also multiple sclerosis. 
4.2.3. Antibacterial Activity 
Novel effective antibacterial agents are extremely needed to fight the increasing seri-
ous problem of drug-resistant bacterial infections, claiming the lives of millions of people 
worldwide [209]. It is the alarming global problem and serious challenge. Short peptides, 
due to their unique features, are considered as antibiotics of the future [11]. DKPs have 
great potential in this area due to their specific features (Table 7), mentioned earlier. In 
particular, proline-based DKP, a known example of DKP classic antibiotic, is bicyclomy-
cin, which is produced by Streptomyces sapporonensis and S. aizunensis against diarrhea 
[210–213]. It is also a rho (a member of the RecA-type ATPase) inhibitor [213]. Cyclo(L-
Leu-L-Pro) was found to inhibit the growth of Vancomycin-resistant Enterococcus faecalis 
strains with MIC value of 12.5 μg/mL, an important finding as these types of strains are 
sometimes untreatable by any current antibiotic or antibiotic combinations [214]. The 
combination of cyclo(L-Leu-L-Pro) and cyclo(L-Phe-L-Pro) was synergistic with MIC val-
ues of 0.25 to 1 μg/mL and was found to be active also against Micrococcus luteus, Esche-
richia coli, Candida albicans, Staphylococcus aureus, and Cryptococcus neoformans with MIC 
values of 0.25 to 0.5 μg/mL [32,215]. Other antibiotics, such as avrainvillamide, speramide 
A, fumitremorgin C, tryprostatin B, spirotryprostatin, are active against multidrug-re-
sistant bacteria [32,41]. Cyclo(L-Trp-L-Pro), known as brevianamide F, isolated from ma-
rine fungi Aspergillus fumigatus and Aspergillus sp. and from the bacterium Streptomyces 
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sp., has activity against Gram-positive bacteria [32,216]. Brevianamide S, dimer cyclo(Pro-
Trp)-cyclo(Pro-Trp), with antimycobacterial effect, should not be overlooked. Verpaca-
mides, e.g., cyclo(L-Arg-L-Pro), have both antimicrobial and anticancer activity [217]. In 
another report, seven DKPs from the fermentation broth of Aspergillus fumigatus isolate, 
apart from cyclo(L-Leu-L-Pro) and cyclo(L-Phe-L-Pro), cyclo(L-Gly-L-Pro), cyclo(L-Pro-L-
Pro), cyclo(L-Pro-L-Val), cyclo(L-Leu-L-trans-4-OH-Pro), and cyclo(L-Phe-L-trans-4-OH-
Pro), were found to exhibit weak antibacterial activity inhibiting the growth of Staphylo-
coccus aureus and Micrococcus luteus [218]. Additionally, cyclo(L-Pro-L-Pro) isolated from 
Lucilia sericata demonstrated antibacterial activities against Pseudomonas aeruginosa and 
Micrococcus luteus [219]. Five DKPs possessing the D-configuration for all amino acids, 
cyclo(D-Phe-D-Pro), cyclo(D-Leu-D-Pro), cyclo(D-Pro-D-Val), cyclo(D-Ile-D-Pro), and cy-
clo(D-Phe-trans-4-OH-D-Pro), isolated from bacteria in larvae of mollusks, exhibited 
strong antibiotic activity against Vibrio anguillarum. Structure-activity relationship studies 
revealed that at least one D-amino acid was required for antibacterial activity and that 
even better MIC was obtained in the case of D-, D- enantiomers [220]. Finally, the in vitro 
synergistic antibacterial activity of six proline-based DKPs, cyclo(D-Pro-L-Phe), cyclo(L-
Pro-L-Met), (cyclo(D-Pro-L-Leu), cyclo(L-Pro-L-Phe), cyclo(L-Pro-L-Tyr), and cyclo(L-Pro-
D-Tyr), and cyclo(D-Pro-L-Tyr)) was investigated in combination with two different anti-
biotics. The results showed synergistic interaction with imipenem, whereas a combination 
of certain cyclic dipeptides with ceftazidime was additive, suggesting a potential role in 
delaying the development of resistance. The cytotoxicity of cyclic dipeptides was evalu-
ated against VERO cell line (African Green Monkey kidney cell line), and no cytotoxicity 
was recorded for concentrations up to 100 μg/mL [202,221]. 
Table 7. Antibacterial DKPs. 
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Among antibacterial agents, DKP alkaloid—actinozine A, cyclo(2-OH-Pro-L-Leu), 
but also cyclo(2-OH-D-Pro-L-Leu), cyclo(D-Pro-L-Phe), and cyclo(L-Pro-L-Phe) can be 
mentioned as well [222,223]. 
In addition, cyclo(L-Pro-L-Leu) isolated from Aspergillus aculeatus has antibacterial 
activity, mainly against Escherichia coli [224]. 
Moreover, indole DKP alkaloids, such as spirodesmin A and verruculogen, should 
not be overlooked [57]. 
Quorum-Sensing Agonists and Antagonists 
In regard to quorum sensing, proline- and hydroxyproline-based DKPs were found 
to influence cell–cell signaling, offering alternative ways of biofilm control by interfering 
with microbial communication [225–229]. Cyclo(L-Leu-L-Pro) and cyclo(L-Pro-L-Tyr) 
found in Pseudomonas putida, were able to activate the biosensor strain Agrobacterium tu-
mefaciens NT1 [221,230]. Holden et al. reported the activation of quorum sensing in Chro-
mobacterium violaceum by cyclo(L-Pro-L-Val) [39]. In another study, cyclo(L-Phe-L-Pro) 
produced by Vibrio vulnificus was found to activate the quorum sensing on an E. coli bio-
sensor strain by modulating the expression of the gene encoding OmpU protein [231]. 
Finally, cyclo(L-Phe-L-Pro) and cyclo(L-Pro-L-Tyr) produced by Lactobacillus reuteri, were 
reported to interfere with quorum sensing in the Gram-positive S. Aureus [41,221,227,232–
234]. 
4.2.4. Antifungal Activity 
Many proline-based DKPs have been characterized for antifungal indications. For 
instance, cyclo(L-Gly-L-Pro), cyclo(L-Arg-D-Pro), cyclo(L-Arg-L-Pro), cyclo(L-His-L-Pro), 
and cyclo(L-Pro-L-Tyr) were reported to inhibit the growth of Saccharomyces cerevisae [235]. 
Additionally, Kumar et al. reported the isolation of proline-containing DKPs, namely cy-
clo(D-Pro-L-Leu), cyclo(L-Pro-L-Met), cyclo(L-Pro-L-Phe), cyclo(D-Pro-L-Phe), cyclo(D-
Phe-L-Pro), cyclo(D-Pro-D-Phe) and cyclo(L-Pro-D-Phe) isomers, as well as cyclo(L-Pro-
L-Tyr), and cyclo(L-Pro-D-Tyr) from a culture filtrate of a Bacillus bacterial strain associ-
ated with an entomopathogenic nematode. These cyclic dipeptides showed significantly 
higher activity than the commercial fungicide bavistin against Fusarium oxysporum, Rhi-
zoctonia solani, and Pencillium expansum [227,236,237]. Cyclo(L-Pro-L-Leu), cyclo(D-Pro-L-
Leu), and cyclo(D-Pro-L-Tyr) displayed superior antifungal activity against Aspergillus fla-
vus, Candida albicans, and F. oxysporum [41]. Cyclo(L-Met-L-Pro), isolated from P. aeru-
ginosa, and cyclo(L-Leu-L-Pro) is an antifungal agent isolated from Streptomyces sp. and 
the bacterium Achromobacter xylosoxidans with activity against diverse fungi [32]. Another 
example of antifungal against is cyclo(L-Phe-trans-4-OH-L-Pro) [40]. Moreover, DKP de-
rivatives, such as cis-cyclo(Pro-3-chloro-Tyr) and trans-cyclo(Pro-3-chloro-Tyr) from ma-
rine sediments in Aegean and Ionian seas can be mentioned too [18]. 
Moreover, DKPs, especially those containing proline, as chitinase inhibitors, can act 
as insecticides, fungicides, and antimalarials. DKPs are chitinase inhibitors. Chitin, poly-
mer of N-acetylglucosamine, is a key element of diverse pathogens (fungal, nematodal, 
and insect). Chitinases, hydrolyzing chitin, play an essential function in the life cycle of 
pathogens and pathogenesis [32,238–240]. Cyclo(L-Arg-D-Pro) and cyclo(L-His-L-Pro), 
produced by the marine bacteria Pseudomonas, inhibit the growth of Saccharomyces cere-
visiae through mimicking an intermediate structure in the pathological cycle of chitin 
[241]. It is an appealing lead compound drug [74]. In this context, cyclo(L-Phe-L-Pro) and 
cyclo(L-Phe-trans-4-OH-L-Pro) are antifungal compounds as well [40]. 
4.2.5. Antiviral Activity 
DKPs containing proline motif exhibit diverse antiviral activities. In this context, 
there are intriguing indole DPK alkaloids, which are widely distributed secondary metab-
olites of microorganisms in fungi Aspergillus, Penicillium, Pestalotiopsis, and Chromocleista, 
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and have diverse bio-activities [57]. Marine-derived proline-based DKP alkaloids, such as 
haenamindole, produced by Penicillium sp. [14,242], raistrickindole from P. raistrickii [113], 
showing activity against the hepatitis C virus, are good examples. Furthermore, rubrum-
lines from E. rubrum [14], the indolyl DKP derivatives, and aspamide DKPs, isolated from 
the Aspergillus versicolor, endophyte from the sea crab, Chiromantes haematocheir, revealing 
anti-influenza A activity [243] are worthwile too. The latter may be helpful in the treat-
ment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [243]. Moreo-
ver, eutypellazines, thiodiketopiperazine-type alkaloids from Eutypella sp. present an in-
hibitory effect in relation to the human immunodeficiency virus (HIV) with low cytotoxi-
city [244]. Epicoccins isolated from the Epicoccum nigrum are another example of proline-
containing DKP derivatives causing HIV inhibitory effect [245]. Notably, DKPs are good 
anti-HIV drugs with high selectivity and few side effects. They inhibit HIV infection and 
replication [8]. DKPs, as chemokine receptor antagonists, act against multidrug-resistant 
strains of HIV [41]. Other examples of antiviral DKPs are cis-cyclo(L-Leu-L-Pro), cis-cy-
clo(L-Phe-L-Pro), and cis-cyclo(L-Val-L-Pro) acting mainly as inhibitors to the prolifera-
tion of influenza A virus (H3N2), but also against plant and human pathogenic fungi 
[246]. Cyclo(L-Tyr-L-Pro) isolated from the Red Sea Spongia officinalis, reveals a strong ef-
fect as a hepatitis C virus protease inhibitor [247]. It should be mentioned that haenamin-
dole has weak inhibitory activity against the hepatitis C virus with the IC50 value of 76.3 
μM [14]. Cyclo(L-Phe-trans-4-OH-L-Pro), the same as cyclo(L-Pro-L-Leu), cyclo(4-trans-
hydroxy-L-Pro-L-Leu), and cyclo(4-trans-hydroxy-L-Pro-L-Phe) isolated from Streptomy-
ces gougerotii GT and Microbulbifer variabilis exhibited a significant reduction effect on the 
dengue virus type 2 replication [248]. 
Furthermore, we can highlight that gliotoxin, mycotoxin containing proline-based 
DKP core, is an either antiviral or anticancer, antimicrobial, antifungal, and immunomod-
ulatory agent. 
Clomycin, albonoursin, ambewelamides, and phenylahistin were reported as agents 
with antibacterial, antiviral, and immunosuppressive properties [249]. DKP derivatives 
containing proline moiety play a role of inhibitors of viral haemorrhagic septicemia virus 
(VHSV), a deadly salmonid rhabdovirus of economic importance in the aquaculture in-
dustry [250]. 
Nucleoside Natural Products 
Nucleosides, as the parts of DNA/RNA, are important elements for cells and their 
metabolic pathways, e.g., energy donors, second messengers, enzyme cofactors. Nucleo-
side natural products are secondary metabolites of microbes. They offer wide range activ-
ity, not only antibacterial, antifungal, antiviral, but also antitumor. In this context, proline-
containing DKPs are promising for drug discovery, especially antibiotic development 
[251,252]. 
4.2.6. Anthelmintic Activity 
Drimentines have anthelmintic activity against various parasites [253–255]. DKPs 
demonstrate an antimalarial effect [256–259]. Naseseazine C, isolated from a marine sedi-
ment derived Streptomyces sp., as well as DKP from Metarhizium sp. fungi, have moderate 
activity against malaria parasites [260,261]. Gancidin W, isolated from Streptomyces sp., 
showed low-toxicity antimalarial effect [262]. Furthermore, the DKP alkaloids, cyclo(L-
Pro-L-Leu), cyclo(L-Pro-L-Phe), and tryprostatin B are active against amastigote-like 
forms of Leishmania amazonensis and intracellular amastigotes of Leishmania infantum [263]. 
They inhibit Leishmania donovani, a fly-borne protozoan that causes visceral leishmaniasis. It 
is noteworthy that antileishmanial DKP alkaloids from the endophytic fungus Tricho-
sporum sp. also exhibit antimalarial, antifungal, and antibacterial activities [264]. 
Fumitremorgin B and verruculogen are potential growth inhibitors of the parasites 
Leishmania donovani as well as Trypanosoma brucei brucei [57]. 
Biomolecules 2021, 11, 1515 44 of 66 
 
4.2.7. Antitoxin Activity 
Cyclo(L-Leu-L-Pro) and cyclo(L-Ala-L-Pro) are inhibitors of production of aflatoxin, 
carcinogenic toxin, produced by Aspergillus sp. [265,266]. Notably, proline moiety is criti-
cal to inhibitory activity. The cis-trans proline isomerism of the N-alkylamide bond in the 
DKPs is involved in the receptor-mediated bio-activity [267,268]. The relationship be-
tween this activity and molecular configuration can be crucial in defining the inhibition 
mechanism of DKPs [265]. 
4.2.8. Antagonists of G protein–Coupled Receptors 
G protein-coupled receptors (GPCRs) are the largest family in the genome, impli-
cated in different diseases, such as cancer, Alzheimer’s disease, depression, type 2 diabe-
tes mellitus, obesity etc., and represent therapeutic targets. 
Interestingly, the chemokine receptor 5 (CCR5) antagonists, on the basis of 2,5-DKP 
scaffold, which was developed for the anti-HIV drug Aplaviroc, belong to a GPCR class 
[32,82]. The potential of DKPs in relation to classical GPCRs is described below. 
Inhibitors of GABAergic Receptors 
GABA (gamma-aminobutyric acid) antagonists are drugs inhibiting the action of 
GABA inhibitory neurotransmitters in the central nervous system. Cyclo(His-Pro) is a cy-
clic dipeptide endogenous to the brain due to its structural similarity to tyreotropin-re-
leasing hormone [269]. Its aza-analogs are a promising scaffold in the discovery of next-
generation GABA inhibitors [270]. Piperazinediones reveal anxiolytic activity through the 
modulation of GABAergic transmission [271]. 
Antagonists of Serotoninergic 5-HT1A Receptors 
Proline-based arylpiperazine 2,5-DKPs bind with high affinity and selectivity to the 
5-HT1A receptor, revealing an improved anxiolytic profile [32,272,273]. 
Antagonists of Oxytocin Receptor 
Oxytocin, parathyroid hormone, and alpha-melanotropin have relevance in the oc-
currence of preterm birth. DKP core facilitates the design and optimization of novel agents 
to either complement or antagonize the action of the parent hormone [17,23,274–278]. 
DKP-based retosiban, and epelsiban, more potent than early non-DKP-based atosiban, 
was previously developed as an oral drug for the prevention of premature labor [278–
280]. However, proline-based DKPs as potent and selective antagonists provide effective 
approaches [278,280] in the treatment of sexual dysfunction, e.g., premature ejaculation, 
either the treatment or prevention of benign prostate hyperplasia is also worthwhile 
[32,281,282]. 
4.2.9. PDE-5 Inhibitors 
DKPs can act as efficient inhibitors of phosphodiesterase-5 (PDE-5) useful in the 
treatment of sexual/erectile dysfunction [78,283,284] as a revolutionary approach. A well-
known example is tadalafil (and its analogs), which is a highly potent and highly selective 
drug [79,80,285–287] with limited adverse effects [288] and a prolonged action [289,290]. 
Notably, tadalafil has the longest half-life of the PDE5 inhibitors. 
4.2.10. PAF Inhibitors: Anti-inflammatory Activity and Beyond 
PAF, a D-glycerol-derived phospholipid, a potent endogenous mediator of inflam-
mation, generated via diverse cells, evokes its bio-activity through interaction with spe-
cific G-protein coupled receptors, platelets, neutrophils, and other inflammatory cells 
[32,291–293]. PAF has relevance in diverse dysfunctions, such as mainly anaphylaxis and 
inflammation, but also asthma, acute respiratory distress syndrome, respiratory infec-
tions, bronchitis, cardiovascular disease, myocardial infarction, arthritis, pain, shock, 
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sepsis, autoimmune diseases, multiple organ dysfunction syndrome, inflammatory bowel 
disease, ischemia, ophthalmic inflammation, psoriasis, neoplastic diseases, ulcerative co-
litis, allergies, Crohn’s disease, cystic fibrosis, emphy Sema, or gastrointestinal ulceration. 
In addition, PAF mediates platelet aggregation, while PAF antagonists protect amyloid-
beta damaged neurons from microglia mediated death [32]. Interestingly, DKPs can play 
a role of PAF inhibitors useful in the treatment of all these dysfunctions [32,294]. More 
specifically, cyclo(His-Pro), the same as cyclo(Pro-Gly), cyclo(Pro-Ala), cyclo(Pro-Ile), cy-
clo(Pro-Leu), cyclo(Pro-Ser), cyclo(Pro-Glu), cyclo(Pro-Gln), cyclo(Pro-Cys), cyclo(Pro-
Met), cyclo(Pro-Phe), cyclo(Pro-Trp), cyclo(Pro-Tyr), cyclo(Leu-Pro), cyclo(Val-Pro), cy-
clo(Leu-hydroxy-Pro), and cyclo(Gly-Pro) are a good example of anti-inflammatory 
agents [74,179,181,295–297]. The latter also has anti-nociceptive effect [298], while cy-
clo(Leu-Pro) has anti-stress, cytoprotective and genoprotective properties, apart from an-
timicrobial, antifouling, antimutagenic, carcinogenic activities [299]. The majority of men-
tioned proline-based DKPs, are isolated from Pseudomonas sp., and inhibit pro-inflamma-
tory cytokines, alleviating crystal-induced renal injury. In other words, they possess pro-
tective effect in renal nephropathy. With this background, they are non-cytotoxic, and 
promising in the development of drugs to treat diverse chronic inflammatory diseases, 
with cyclo(Val-Pro) as a new lead [297]. Furthermore, cyclo(Pro-Tyr) is an example of 
promising anti-platelet drugs against influenza A [300,301]. On the other hand, DKP al-
kaloids from Aspergillus sp., aspechinulins, have antiviral activity and either an anti-in-
flammatory or antibacterial effect [178,302].  
In the case of asthma, we should mention theophylline, a natural substance also used 
in the treatment of other respiratory disorders, such as chronic obstructive pulmonary 
disease [303]. 
Cyclo(Pro-Ile), cyclo(Pro-Leu), cyclo(Pro-Trp) exhibited inhibition of 12-O-tetradeca-
noylphorbol-13-acetate (TPA) inducing ear edema. They can be useful in the treatment of 
inflammatory disorders such as arthritis, rheumatism, myalgia, and allergic dermatitis 
[21]. 
4.2.11. Cardio-Metabolic Disorders 
There are several reports in the literature describing the relevance of proline-based 
DKPs in cardio-metabolic dysfunctions. Firstly, the calcium-channel-blocking effect of 
DKPs was proposed [304] with cyclo(Trp-Pro) blocking channels, and confirmed later 
[192]. In addition, verrucologens from fungus Penicillium verruculosum are neurotoxins 
that can block Ca2+ activated K+ channels [305]. The ability of blocking sodium channels by 
DKPs should not be neglected [306]. Next, the potential of DKPs in the treatment of car-
diological dysfunctions with an antiarrhythmic effect of cyclo(Trp-Pro) was presented 
[307]. They have relevance in the treatment of hypertension, and congestive heart failure 
[306]. Cyclic glycine-proline, a natural nutrient, normalizes blood pressure in obese rats 
[186]. Cyclo(L-His-L-Pro), mentioned earlier, also plays a cardiovascular role. It exhibits 
endocrine and electrophysiological effects [176]. Notably, ~430 million people worldwide 
suffer from diabetes, and it will reach the seventh cause of death by 2030 [308,309]. Cur-
rent drugs are not sufficient because of the side effects, such as weight gain, liver damage, 
and allergic reactions [309]. Antihyperglycaemic activity of DKPs is well-documented in 
the literature [310,311]. Proline-based DKP alkaloids, from marine fungi, can provide a 
new platform for the discovery of a drug [312]. Cyclo(His-Pro) decreases the level of blood 
glucose [176]. 
Pancreatic lipase is an important enzyme in relation to the digestion of dietary tri-
glycerides. Thus, its inhibition is a promising target in the context of obesity treatment. 
Cyclo(D-8-acetoxyl-Pro-L-Leu), isolated from the Streptomyces sp. revealed preferable anti-
lipase activity, and could be well bound with the catalytic pocket of the pancreatic lipase 
[14,313]. 
Interestingly, cyclo(L-His-L-Pro) inhibits mainly appetite but also the desire for alco-
hol [21,314]. 
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4.2.12. Hemo-Regulation 
N-subsituted DKPs dimeric forms, including linker of di-proline-based DKP entities 
and 1,4-phenylenedimethyl, show hemo-regulatory activities, and may be useful to stim-
ulate hematopoiesis [21,315]. 
4.2.13. FSH Receptor Antagonists 
Among the glycoprotein hormones used in infertility treatment, follicle-stimulating 
hormone (FSH) is the major value driver for therapeutic intervention. Without the FSH 
treatment, there is no ovarian hyperstimulation. DKPs can modulate FSH receptor and 
were considered as lead structures [8,316,317]. 
4.2.14. Immunosupressants 
Some DKPs possess immunosuppressive properties. In particular, chetomin and 
gliotoxin are of relevance to the inhibition of macrophage phagocytosis, mitogen-acti-
vated T cell proliferation [283,318]. Other known examples are tardioxopiperazines, from 
the Ascomycete, and cristatin A, from the plant Lepidagathis cristata [32]. 
4.2.15. Heat Shock Response 
Asparaprolines, asparagus-derived proline-containing 3-alkyldiketopiperazines, 
mainly cyclo(L-Phe-L-Pro), cyclo(L-Tyr-L-Pro), and cyclo(L-Leu-L-Pro), exhibit heat shock 
protein 70 mRNA induction activity. In more details, the heat shock response, a highly 
conserved mechanism in organisms, play important role in resetting of the circadian clock 
in relation to extreme proteotoxic insults (heat, oxidative stress, ultraviolet radiation, 
heavy metals, toxins, and bacterial infection). The response is mediated at the transcrip-
tional level via heat shock elements, in the upstream area of genes encoding heat shock 
proteins. Chaperons, members of heat shock protein 70, cause cytoprotective activity 
through increased cell viability and promotion of protein damage repair. Thus, thanks to 
antiapoptotic and anti-inflammatory properties, heat shock proteins are therapeutic tar-
gets in relation to inter alia regulation of circadian rhythm and sleep, antiulcer drugs, pre-
vention/treatment of diseases caused by protein misfolding such as neurodegenerative 
disorders or cystic fibrosis [319]. 
4.2.16. Photoprotective Agents 
DKP derivatives have skin photoprotective potential as safe and more eco-friendly 
agents [320]. 
4.2.17. Activators of Dioxygen in Oxidative Processes 
Proline-based DKPs, including aromaric derivatives, act as catalytic mediators for 
chemoselective aerobic oxidation processes, such as sulfides oxidation, alkenes epoxida-
tion, or the oxidative coupling of phenols [321]. Cyclo(Pro-Pro) is an archaic precursor in 
the evolution of life, rendering its potential role in the activation of dioxygen of tremen-
dous importance. Proline ‘could condense to afford DKPs under potentially prebiotic al-
kaline aqueous conditions with high yield’ [5,38]. 
4.2.18. Biological Herbicides and Plant Growth Regulation 
Synthetic herbicides can lead to increased human health risks, environmental pollu-
tion, and the evolution of resistant weeds. Thus, bio-herbicides from natural sources are 
required. DKPs are promising nature-inspired herbicides due to their environmental 
friendliness, safety, high selectivity, and probable new target sites [322–324]. Proline-de-
rived DKPs have specific herbicide activities [32]. Notably, proline is linked to diverse 
plant stresses as defense against toxicity [325]. It is used by a plethora of organisms in 
protection against the cellular imbalance resulting from environmental stress [326]. The 
proline improves the formation of reactive oxygen species, signaling, cellular apoptosis 
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[327–329]. The maculosin-like peptides cyclo(L-Tyr-L-Pro), but also cyclo(L-Phe-L-Pro) 
produced by Alternaria alternata were investigated as potent safe, and environmentally 
friendly agents [32,91]. Thus, proline-based maculosin and its analogs are a specific herb-
icide [21].  
DKPs containing acylhydrazone exhibit insecticidal activity to Plutella xylostella and 
Culex pipiens pallens [330]. DKP alkaloids are important secondary metabolites of mi-
crobes. Indole DKP alkaloids are the condensation products of tryptophan with a second 
amino acid-like L-proline [105,312,331]. 
Okaramines can play the role of insecticide [32].  
DKPs within a 4-hydroxyproline, such as cyclo(L-Phe-L-4R-Hyp), cyclo(L-Leu-L-4R-
Hyp) and cyclo(L-Ala-L-4R-Hyp), isolated from Alternaria alternata, are active against the 
pathogen fungus Plasmopara viticola, but non-toxic for the vine plant [21]. 
Cyclo(D-Pro-L-Val), cyclo(L-Pro-L-Ile), cyclo(L-Pro-L-Phe) are useful in the treatment 
of tree diseases, which devastate pine forests worldwide [28]. 
The hydroxyproline analog cyclo(L-Pro-L-trans-OH-Pro), isolated from a Ruegeria 
strain of bacteria, acts towards plant-growth regulation [32]. Furthermore, brevicompa-
nine, proline containing DKP-derived compound from fungus Penicillium brevicompactum. 
plays a role of plant growth promoter [332]. 
4.2.19. Biotechnological Applications 
Bone Tissue Engineering 
It is a rapidly growing field with the objective of generating a bio-functional tissue, 
which is able to treat diseased or damaged tissues. The number of orthopedic surgery 
procedures is projected to ~28 million by 2022 [333]. Therefore, alternative scaffold fabri-
cation techniques are extremely needed in organizing the final, better structure-mechani-
cal properties, and biological response of the implanted biomaterials [334]. DKPs are po-
tential scaffolds for bone regeneration. They can be used in various bone-related applica-
tions, inter alia bone defect, and fracture healing, osteoporosis, osteopenia, and many 
more [333]. DKPs induce osteogenic differentiation, and support osteogenesis with no cy-
totoxicity. DKP-like compounds (e.g., protuboxepins) are promising inhibitors of induced 
osteoblastic differentiation. They can offer benefits for fibrodysplasia ossificans progres-
siva. It is a rare disease causing progressive and widespread heterotopic ossification in 
soft tissues (muscle, tendons, and ligaments), but surgery is prohibited due to severe het-
erotopic ossification induced by injury to soft tissues. On the other hand, no drugs have 
been approved so far. Therefore, DKP-derived agents give a glimmer of hope [335]. 
Vaccinology 
Vaccines are among most successful medical interventions. Vaccines recruit the 
body’s immune system to protect the host from infections or cancer. Modern vaccine for-
mulations are typically comprised of antigen (immunogen) and adjuvant (immune stim-
ulating component) [336]. The antigens are fragments of the targeted pathogen against 
which an immune system builds the response. Peptide epitopes are minimal antigens and 
can be divided into two groups: T-cell epitopes, which trigger either cellular or assist-
ing/helper immunity, and B-cell epitopes, which induce humoral immunity [337,338]. Pro-
tein antigens typically include several of these epitopes [337,339]. Both peptides and pro-
teins are often inadequately immunogenic, thus adjuvant are required to boost the immu-
nogenicity of vaccine antigen(s) [340]. A wide variety of molecules have been investigated 
as potential adjuvants for vaccine delivery, including peptides [341–349].  
DKPs have not been used as vaccine antigens to date. However, they are structurally 
rigid and easy of modification, thus, could act as peptidomimetic antigens in the future 
[55,350]. B-Cell epitopes are predominantly discontinuous, and the quality of the antibody 
response depends on the antigen structural conformation. Therefore, the conformational 
properties and customization ability of DKP might be employed for antigen design 
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[11,351]. DKP can facilitates orienting amino acid’s side chains at ‘stereo-correct‘ distances 
and angles to superimpose those of native epitopes. Such antigens could additionally be 
tailored to resist enzymatic degradation [352], thus adapted for oral delivery, and can bear 
additional targeting moieties for improved delivery to lymph nodes. Further, the rigid 
structures of DKP-based peptidomimetic antigens could improve immune recognition of 
epitope’s parent protein compared to the highly flexible standard peptide antigens.  
In the vaccine design DKP can be employed not only as peptidomimetic antigens. 
For example, DKPs have been recently used as transfection agents in mRNA-based vac-
cine formulations [353]. The formulation was based on a phospholipid-based lipid nano-
particles (LNPs) loaded with mRNA that encoded a pathogenic antigen, intended to trans-
fect host cells. Upon immunization with such vaccine, host cell should express the antigen, 
which is then recognized by immune cells initiating the immune response. To achieve it, 
the vaccine formulation must escape endosomes, where mRNA could degrade if exposed 
to enzymes. Therefore, charge altering DKPs were used as endosome escape agents in this 
mRNA-LNP formulation to generate proton sponge effect enabling translation of mRNA 
cargo [353]. The DKP-bearing vaccine was highly immunogenic and triggered a long-last-
ing Th1-responses, with increased IFN-γ+ CD4+ and CD8+ T-cell counts and generated high 
IgG titers. 
Natively derived DKPs were recently employed as immunomodulatory agents; to 
alleviate adverse events or disorders arising from inflammatory immune responses. As-
partyl-alanyl DKP fragment in human serum albumin was found to trigger immunomod-
ulatory effect, via RIP-1-dependent suppression of IFN-γ expression from T-cells, render-
ing them anergic [354]. A self-administrable, anti-inflammatory intranasal product based 
on this DKP fragment was launched (Ampion®) [355], and currently being investigated 
for alleviating of severe symptoms in COVID-19 patients (Phase-1, NCT04839965).  
DNA Delivery 
DKP-based cell penetrating peptidomimetics enable efficient cellular uptake and 
DNA delivery, via specific noncovalent interactions [74,356]. Incorporation of cyclic pep-
tides improves tolerability against proteases [45]. These mimetics contain lysine and as-
partic acid [356]. However, proline-containing cell-penetrating peptides present the great-
est penetrating activity, among amino acids, in relation to effective transport of DNA 
[357,358]. 
Fluorescent DKPs 
They are excellent future scaffolds to form optical agents useful in inter alia smart 
molecular bio-imaging or activatable fluorescent pro-drugs, while other applications will 
appear in the coming years. More specifically, drug discovery programs for cell repro-
gramming or mechanistic studies to characterize cells in tissue microenvironments and 
clinical applications are the main areas where highly specific probes are needed. They can 
be helpful in building dual probes with a multimodal character, compatible with diverse 
imaging modalities, as well as probes of theranostics to deliver imaging reporters, or ther-
apeutic loads. Fluorescent DKPs will play an important role in the development of new 
smart therapies for personalized medicine. Moreover, proline-containing DKPs, provid-
ing extra bio- and conformational features, have potential. We can mention nano-chromo-
phores on based on the self-assembled proline-based cyclo-dipeptides or fluorophore-
bearing oligomers of DKPs for the intracellular DNA delivery [359]. Notably, the self-as-
sembled, well-ordered structure of DKPs leads to much better fluorescent properties [360]. 
Inhalable Powder Formulations 
DKPs are utilized in the development of innovative forms of delivery systems, such 
as technosphere dry powder formulation for drugs administration into the pulmonary 
system. The formulation of insulin-loaded fumaryl DKP microparticles suitable for 
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inhaled delivery (Afrezza) is a good example [74,361]. It is an interesting, new option for 
subcutaneous injection, which is an inconvenience for patients, and lead to many side ef-
fects such as fat atrophy or fat hyperplasia at the injection site, and unsatisfactory blood 
glucose control [362]. In comparison with other non-injection routes (oral preparation, 
transdermal patch, pulmonary inhalation, or nasal mucosal administration) it is better due 
to its physiological advantage. More specifically, alveoli have a large surface area, high 
permeability, low toxicity, and large circulation perfusion, good lung deposition inhala-
tion, which could rapidly decrease the blood glucose level without immune stimulation, 
and the drug can be quickly absorbed into the blood circulation, preventing both drug 
decomposition by digestive intestine enzyme and ‘first pass effect’ of the liver [74,361,362]. 
Pheromonal Scaffold 
Diatoms, an important ecological group of phytoplankton, an extremely diverse 
group of microalgae, offer possibilities for biotechnological applications, e.g., sustainable 
pest control in agriculture [363,364]. The proline derived DKP, cyclo(L-Pro-L-Pro), has 
been recently reported as the first molecular structure of sex-inducing pheromone from 
marine diatom, Seminavis robusta sp., with moderate to good bioactivity, and low to no 
phytotoxicity [365]. Interestingly, diatom-based DKPs have relevance in biofuel produc-
tion [366]. 
5. Supramolecular Structuring of DKPs 
Cyclo-dipeptides, as important biomolecules, provide promising minimalistic scaf-
folds for self-assemblies in terms of molecular recognition, aqueous processability, ther-
mal stability, biocompatibility, structural, and functional versatility towards developing 
innovative therapeutic modalities, with increased efficacy and reduced side effects. A self-
assembly is a process of linking molecules via noncovalent (supramolecular) interactions 
into (bio)functional systems (assemblies, called supermolecules). It can be observed in liv-
ing organisms, from bacteria to humans. It is useful in arranging bio-machinery, including 
the DNA double helix, ribosomes, the quaternary structure of enzymes as well as bio-
entities, such as cell membranes, the helical structure of collagen, or cytoskeleton 
[201,367]. Thus, from the supramolecular point of view, non-covalent interactions provide 
special systems which help to understand bio-processes and create innovative bio-mate-
rials that are able to promote 3D cell growth with increased proliferation and differentia-
tion [368]. In this field, DKPs have an inherent tendency to take part in intermolecular 
interactions driven by specific hydrogen bonding patterns leading to highly organized 
artificial nanostructures. In particular, DKPs contain four main H-bonding sites, well-ori-
ented H-bond donors, and acceptors, enabling the formation of gelators. In addition, weak 
forces, such as π…π stacking, hydrophobic effect, electrostatic interactions, act as catalysts 
by templating unique arrangements toward easier gellation [369]. Notably, peptide-based 
hydrogels are a new great promise for diverse bio-nano-applications, inter alia in tissue 
engineering or therapeutics delivery [369]. DKP-based supramolecular hydrogelators are 
promising in anti-infectious vaccination, also in cancer immunotherapy, mainly because 
they enhance either the vaccines potency or delivery. They can be excellent novel, safer, 
and more potent adjuvants. In this context, they have high stability, while the costs of 
production are low. Moreover, they can be produced and modified in large quantities in 
an easy way [370]. DKP-based low molecular weight gelators also find applications in 
encapsulation of drugs [74,370]. Self-assembled functional proline containing DKP-based 
bio-nano-materials have superior structural rigidity and in vivo stability provided by the 
DKP ring. On the other hand, they display dynamic features such as morphological flexi-
bility [369]. They can cross the blood-brain barrier, and reach difficult pathological targets, 
offering versatility of desirable biophysical properties. They have broad-spectrum pro-
spectives in bio-medicine, such as high strength biomaterials, isothermal, and injectable 
gelation in (stimuli-responsive) the delivery of drugs and other bioactive molecules (as 
well as gene), or 3D bio-printing, smart bio-nano-architectonics, microfluidic devices, bio-
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sensing, and point-of-care diagnostics, hierarchical biomimetics [367,370]. DKP 
nanostructures can encapsulate biomolecules, fluorescent dyes and deliver them inside 
cells. These theranostics have enhanced efficacy [368]. In addition, we should mention 
proline-rich cyclic peptides which due to size and complexity, can provide useful scaffolds 
for modulating more challenging biological targets, such as protein–protein interactions 
and allosteric binding sites [371]. The proline-based DKP scaffold is highly promising and 
should inspire researchers to develop other appealing smart self-assembled bio-applica-
tions toward an effective clinical translation [372]. In particular, targeting domains to pro-
mote receptor binding and to achieve cytoplasmic/nuclear engaging drug delivery appli-
cations, can be included [368]. Therefore, better understanding of the nature of self-assem-
bly behavior is required [368]. The design of DKP-based self-assembled materials still is a 
challenge. 
From this point of view, a deep insight into the structural landscape of these supra-
molecular materials can help to understand the modulation mechanism of DKP self-as-
semblies. The nature of self-assembly depends on the information encoded in the molec-
ular building motifs called synthons [367]. The term ‘molecular synthon‘ was introduced 
by Corey as ‘structural unit within molecules which can be assembled by known or con-
ceivable synthetic operations’ [373], and developed to ‘supramolecular synthon’ by De-
siraju as ‘structural units formed with intermolecular interactions’ [374]. Both the self-as-
sembly process and applications of the final supramolecular systems (materials) can be 
modulated by a suitable recognition and design of synthons [367]. Synthons should be 
robust enough to exchange from one network to another. The proline-based DKP 
synthons are a bottom-up approach of great importance, providing inspiring self-assem-
bly building blocks to develop bio-functional architectures with appealing, innovative ap-
plications of advanced, next generation theranostics, biomimetics, biomaterials, as well as 
to tune their features via a proper choice of amino acid and stereochemistry of DKP-
synthons [32]. 
Supramolecular interactions forming building motifs (synthons) are increasingly re-
garded as useful in the design of ideal ligands, inside the protein pocket [375]. However, 
they have potential in the design of bio-functional materials, with desired and controllable 
properties, too. 
Supramolecular interactions, despite their importance in bio-systems, have been 
mostly behind the scenes because of the difficulty of correct detection. Nevertheless, re-
cent advances in structural biology, and better resolution of 3D structures, open a new 
avenue to deeper insight into supramolecular bio-complexes leading to better knowledge 
on the bio-supramolecular interactions engaged in the synthons formation.  
In this context, supramoleculas studies on peptides, simple biomolecules, have pri-
mary importance. In the course of our ongoing project, focused on the supramolecular 
perspective of peptide-based systems [6,11,12,52,53,376–403], a thorough screening of the 
structural databases revealed an appealing sub-family of proline-based DKPs and its an-
alogs. Here, we provide a brief overview of structural databases and library of family of 
proline-based DKP structures as well as key non-covalent interaction motifs in found com-
pounds, included in the Supplementary Materials (Table S1–S3). Notably, the same motifs 
are observed in DKP-based bio-complexes (Figure 2). These findings can be helpful in the 
design of both more effective drugs and smart supramolecular bio-materials.  
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Figure 2. Crystal structure of cytochrome P450 NasF5053 Q65I-A86G mutant variant from Strepto-
myces sp. NRRL F-5053 in the cyclo(L-Trp-L-Pro)-bound state; RCSB PDB ref. code: 6VZA.pdb [234]. 
On the left: The molecular view of supramolecular interactions, showing, e.g., synthon formed by 
(DKP)C = O H-N H-bonding interaction. 
6. Conclusions 
To sum up, cyclic dipeptides offer appealing structural and biological diversity. Most 
recently, more and more interesting DKPs and their derivatives have been isolated from 
natural sources and investigated in relation to novel, impressive bio-functionalities. The 
proline-based DKPs are valuable molecular and supramolecular scaffolds, ‘programmed‘ 
by nature, in synthetic biology and protein engineering, toward tuning either the desirable 
features of modern theranostics, biomimetics, biomaterials, or interactions via a proper 
choice of additional amino acid and stereochemistry of DKP-synthons, which may be fur-
ther chemically modified to increase their bio-activity spectrum. Here, we summarize an 
overview on both the bio-landscape and supramolecular structuring of proline-based 
DKPs and their derivatives on the basis of the latest scientific and patent literature as well 
as structural databases. Proline-based cyclo-dipeptides are extremely compact and stable 
bio-molecules, making noncovalent self-assemblies extra rigid, biomimetic and smart ma-
terials to address complex biological problems, towards innovative biomedical and bio-
technological applications for personalized medicine. Taken all together, we hope that this 
guide will deepen the knowledge on proline-containing DKPs and catalyse further intri-
guing studies in the field of drug discovery utilizing proline-DKP as a versatile scaffold 
for the molecular and supramolecular design of innovative smart therapeutics and bio-
functional self-assembled (nano)materials that have been challenging so far. 
Supplementary Materials: The following are available online at www.mdpi.com/2218-
273X/11/10/1515/s1. Table S1: Crystal structures containing DKP moiety, retrieved from the Cam-
bridge Structure Databases. Table S2. Graphical schemes of selected proline-DKP-based supramo-
lecular synthons Table S3. Library of supramolecular synthons, and interactions engaged in the 
synthons formation, found in proline-based DKP compounds and their derivatives, according to the 
Cambridge Structure Databases. 
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